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ABSTRACT
In this study, the immunogenidty of hPTH(l-34) was assessed in 
mice and rats, using different routes of immunization and two forms of 
hPTH(l-34), free and conjugated. The responder rats and mice were 
used for the production of monoclonal antibodies to hPTH(l-34). 
Several mouse-mouse and rat-mouse hybridoma cell lines were pro­
duced. The antibodies secreted were examined for various characteristics 
and used for the detection of hPTH(l-34) in biological specimens.
Polyclonal antibody was also produced in goat against the free 
hPTH(l-34). Lymphocytes isolated from goat blood were thereafter 
used in the production of monoclonal antibodies. Fusion of goat B- 
lymphocytes with both mouse NS1 myeloma cell line and hetero­
myeloma (ovine-murine hybridoma) resulted in five cell lines secreting 
goat monoclonal antibodies to hPTH(l-34).
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1.1. INTRODUCTION
It was only about 60 years ago that the antibody was accepted as 
serum globulin although long before that the presence of antibody 
activity in the serum had been known. Soon after their recognition as 
part of the serum immunoglobulins, antibodies were characterized and 
studied in terms of their interaction with the antigen and structure.
Antibodies are regarded by immunologists as sensitive and specific 
tools on which many immunological methods depend. Antigen- anti­
body reactions constitute the basis of numorous procedures devised for 
identification, quantitative measurement and isolation of particular 
molecules from a mixture. Approximately 108 different B-lymphocyte 
are present in the spleen of mice and man. Although they were 
derived from a common stem cell, each developed its own capacity to 
make an antibody that recognizes different antigenic determinants. 
As the separation of of various antibodies can be almost impossible at 
times, conventional antisera contain a mixture of antibodies which 
differ from animal to animal, and even between animals which are 
genetically identical. The characteristics of the antibody may also 
differ in the same animal, between different bleeds. Serum immuno­
globulin levels vary with genetic background, antigen load and age.
The idea of one cell-one antibody was proposed in 1959 (Burnet 
1959). This theory predicted that antibodies made by the same cell are 
homogeneous. The mode of production of monoclonal antibodies sup­
ports this theory. Monoclonal antibody is the result of collective 
characteristics of two different cells, one secretes the antibody and 
the other has the capability of growing in culture indefinitely. Thus 
the resulting cell inherits both characteristics, and so produces and 
secretes antibody continuously and reproducibly. . The ability to 
raise, and select specific antibody to individual determinant
demon stratesthe utility of monoclonal antibody technique. Antigen purity
is no longer a necessity. The resulting antibodies have the fine 
specificity to the determinant recognized on the antigen, and so the
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cross-reactivity should be minimal.
Monoclonal antibody has been gradually replacing the polyclonal 
variety in many fields of application. It is chosen, in the main for 
specificity, homogeneity and continuity. However, polyclonal antibody 
will still continue to be used and in certain situations may even be pre­
ferred. For example, polyclonal antibody would be chosen when high 
affinity antibodies are required, as the monoclonal antibody usually 
displays a low affinity (Goding 1986).
1.2. THE IMMUNE SYSTEM
The immune system acts as a third line of defence. Compared with 
lower animals, vertebrates have sophisticated immune systems, 
which respond in a specific manner, distinguishing self from non-self. 
The flexibility and effectiveness of the specific immune response to an 
antigen are provided by the specificity, memory and non-self recogni­
tion characteristics of immune system.
1.2.1. Functional cells of the immune system
The immune system is composed of a number of cells types, and 
between them they neutralize, destroy, and produce antibody against 
the foreign material. The different cells were derived from a common 
stem cell.
There are different immune cells which cooperate in combating 
the foreign antigen. They originally inhabit different primary lym­
phoid tissue from which they get their names. Those abundant in the 
bursar of fabricius in birds or equivalent ^ probably the foetal liver, and 
bone marrow in mamma]s(Miller 1966, Wiessman et al., 1974) are called 
B-cells, and those abundant in the thymus are called the T-cells.
The development and maturation of these cells in the primary 
lymphoid organs is antigen-independent. They migrate from the pri­
mary lymphoid organs, through the blood and lymph network system, 
the B- cells mostly dwell in the primary follicle and T-cells in the 
diffuse cortex (Howard 1972, Sprent 1973). The secondary lym-
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phoid organs provide the environment necessary for the presentation 
and processing of antigen, leading to an antigen dependent mature 
immune response.
Small lymphocytes are the principal cells involved in immune 
response (Hunt et al., 1972, Howard and Gowans 1972), and the 
depletion of lymphocytes abolishes such response. The cooperation of 
the T-cells and B-cells is essential for immune response. Clinical 
diseases which manifest these situations have for many years been 
kown to occur in humans. The Di-George’s syndrome is characterized 
by the absence of T-cells and B-cells are normal or near normal. 
Burton’s syndrome, on the other hand, presents with normal T- cells 
and reduced B-cells.
Although B and T cells are functionally different, they are 
indistinguishable morphologically under light microscopy (Miller 
1974). However, they can be identified by reaction specificity as in 
sheep red blood cell rosette formation (Jondal et al., 1972) and by a 
variety of surface markers (Raff 1971, Loor and Roelants 1975, 
Kieseilow et al., 1975).
It is the functional properties of B and T cells which has been 
utilized in the hybridoma technology. Since the introduction of 
monoclonal antibody technique many B and T cell lines have been used 
in the production of hybridoma and thymoma respectively. The 
cooperation between B and T cells that finally leads to antibody pro­
duction is the target in hybridoma technology.
1.2.2. Immune response
The exposure of the immune cells to a foreign antigen result in 
the stimulation of these cells to combat the antigen. The stimulation of 
the different cells to secret antibody requires the recognition, stimula­
tion, proliferation and differentiation of these cells.
the total antibodies
Although it was estimated that about l-5x 107 represent ~ repertoire 
in an inbred mouse, only 1000-8000 recognize any particular 
antigenic determinant (Kohler 1970,Kreth and Williamson 1973) and
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of these only 5-10 appear in the antisera in response to each antigenic 
determinant (Schreier et al., 1980). This indicates the degree of the 
heterogeneity of conventional antisera and the difficulty in the 
reproduction of animal response.
The clonal selection theory was accepted by immunologists to 
explain the heterogeniety of antibody (Burnet 1959). The heterogene­
ous nature of the immune response was explained by the existence 
.whichof cell population in each cell is capable of producing only one anti­
body. This theory thus emphasizes that the whole cell is the unit of 
selection. Only a small number of cells can be stimulated because 
they possess a receptor for the antigen, while the majority of them 
cannot be stimulated. Later it was confirmed that the receptors are 
immunoglobulins on the curface of the B-lymphocyte (Ada 1970, Raff
1971), and they could be exact copies of the secreted antibody for 
B-cell (Mitchison 1967).
B-cell activation, proliferation and differentiation has been 
recently reviewed (Weigle 1987). It is concluded that two pathways are 
involved in the antigen stimulation of B-cells, MHC-restricted and 
MHC-unrestricted. The activation of MHC-restricted pathway seems 
to be the major route responsible for the significant part of the 
total antibody response, and different sub-population of B-cells dictate 
the response of each pathway.
The acceptance that myeloma proteins are indistinguishable from 
normally secreted immunoglobulin proteins (Weissman 1978, Potter
1972) and the induction of mouse myeloma tumors producing 
homogeneous immunoglobulins (Potter 1972) confirm the essentiality 
of one cell one antibody specificity prediction.
The stimulation of the body immune response involves the 
stimulation of B and T lymphocytes. Events leading to the destruction 
of the antigen involve two immune response pathways depending on 
what type of cell is involved. Humoral immune response involves B- 
cell activation and production of antibodies to neutralize antigens.
INTRODUCTION
- 6 - CHAPTER 1
When the antigen accumulates in the secondary lymphoid tissue, 
stimulation and expansion of antigen specific clones take place 
accompanied with B-T cell cooperation and the formation of 
memory cells which are primed and ready for fast action in the 
second exposure to the antigen. Then antibody is produced and 
released to bind the antigen. When T cells are involved the response 
is known as cell-mediated immune response. They differentiate into 
different specialized types of T cells which destroy the antigen.
1.2.3. Antibody structure and function
The antibody is a large molecule of glycoprotein, consisting of two 
identical heavy chains and two identical light chains linked by disul­
phide bonds (Porter 1967, Edelman 1969, 1970); the two H-L chains 
are also linked by a disulphide bridge. The molecule has different 
regions of constant and variable amino acid sequences. The struc­
ture of immunoglobulin G (IgG) is shown in figure 1.1.
The elucidation of the structure of antibody and the amino acid 
sequence revealed that the light chains are composed of 220 amino 
acids and have a molecular weight of 23000 daltons. The heavy chain 
consists of 440 amino acids and has a molecular weight of 55000 dal­
tons.
The biological properties of the antibody molecule are determined 
by the heavy chain constant region, and the antibody specificity is 
provided by the variable regions of the chain. Table 1.1 summarizes 
the different properties of immunoglobulins. There are only two types
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Figure 1.1: The structure of prototypical Ig. VL vari­
able Light, VH variable Heavy and CL Constant 
Light domain. The first domain of each chain is the 
variable region and the remaining domains comprise 
the constant region of the chain. The disulphide 
bonds (S-S) connecting the L and H chains are always 
between the CL and CHI domains with the precise 
location differ between classes and species . The hinge 
region is the boundary between the CHI and CH2 
domains, this also differs according to class and 
species. (Adapted from Clark 1986).
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Table 1.1
Physical properties of human immunoglobulins
Ig G IgA IgM IgD IgE
No. of subclasses 4 2 - - -
No. of basic units 1 1/2 5 1 1
Heavy chain class 1.2,3,4 1.2 u
Light chain k / \ k / \ k / \ k / \ k / \
Molecular weight 150kd 160kd 900kd 185kd 200kd
Concentration in nor­
mal serum in mg/ml
8-16 1.4-4 0.5-2 0-0.4 17-450 ng/ml
% of total Ig in serum 80 13 6 0-1 0-0.002
%Carbohydrate content 3 8 12 13 12
Half life in serum 23 5.8 5.1 2.8 2.5
Notes:
1-IgG3 half life in serum is only 10 days
2-IgE binds basophils and mast cells and 
have a longer half life in serum.
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of light chain constant region, kappa and lambda, and only one of them 
present in any one antibody molecule.
1.3. MONOCLONAL ANTIBODY
An immu ne response to an antigen involves the activation of 
many cells which secrete antibodies to various epitopes on the 
antigen. These antibodies are called polyclonal antibodies. The antibo­
dies in the serum are a mixture of different antibodies to the same 
antigen and to unrelated antigens to which the animal has had an 
immune response. '
The antibodies secreted by clone of cells derived from a single cell
are called monoclonal antibodies. Under normal circumstances the
isolation and propagation of an antibody-producing cell is impossible
because these cells cannot grow in tissue culture. Hence the fusion 
an
of antibody-producing cell with an immortal myeloma cell was used to 
circumvent the growth and isolation problems. The resultant cells are 
capable of both growing indefinitely in tissue culture and producing and 
secretingantibody. Thus, the isolation and propagation of antibody- 
producing cellsbecame possible.
Although myeloma cells have been known for some time, only ; 
few antigens were found to be bound with the antibody secreted by 
these cells. Their use in the production of monoclonal antibody to 
pre- determined specificity was only introduced thirteen years ago 
(Kohler and Milstein 1975). Since then the technique has been used in 
many laboratories and monoclonal antibodies have been produced 
against a wide range of compounds. A general scheme of monoclonal 
antibody is shown in figure 1.2
In the last decade thousands of articles have appeared dealing 
with different aspects of monoclonal antibody. Improvements in the 
technique, optimization of different steps, manipulation and use of 
monoclonal antibodies have been reviewed extensively (Goding 1986, 
Reading 1982, Foster 1982, James and Bell 1987, Samilovich et al., 
1987, Hubbard 1983).
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Figure l .2: The different stages of lymphocyte hybridiza­
tion. The timing of each stage is shown at the left side of 
the diagram.
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In this review the different steps leading to the production of 
monoclonal antibody will be described in brief, giving the relevant 
literature.
1.3.1. Immunization
Immunization usually implies the administration of an antigen 
in-vivo to specifically activate and differentiate B-lymphocytes. 
Efficient immunization is seen as a key factor for a successful pro­
duction of monoclonal antibody. It depends on the interaction 
between and contribution of different factors. The factors controlling 
the immunogenicity are still poorly understood. The physiological 
state of the host is important in obtaining a good response (Crump­
ton 1974). The recognition of antigen by macrophages is the initial 
event in the immune response (Opitz et al., 1976, Pierce and Klin- 
man 1981, Unanue 1979). Antibody characteristics are deter­
mined at an early stage of B-cell differentiation, where the antibody 
diversity is generated (Leder 1982, Tonegawa 1983),and the function 
effectors are determined late in a process called "class switching" 
(Hon jo 1983).
Theoretically, the intensity of response is not very important in 
the production of monoclonal antibody. On the other hand many 
workers report time and again, that the fusion efficiency depend on 
the response of an animal, and the immunization schedule.
Two methods of immunization are generally used in the generation 
of monoclonal antibody, those which depend on the stimulation of B- 
cells in- vivo and those which depend on the stimulation of B-cells in- 
vitro.
1.3.1.1. In-vivo immunization
Many of the monoclonal antibodies produced were derived 
from in vivo immunization. Despite many years of research immuni­
zation is still regarded as an art than a science, and factors control­
ling it are still poorly understood.
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Many immunization protocols and schedules have been used 
successfully in the production of monoclonal antibodies. However, it 
is well known that the successful production of monoclonal antibody 
require the stimulation and activation of the antigen specific B- 
cells. Hence, lengthy protocols and complicated schedules may not be 
necessary. For example, intrasplenic immunization for nine days have 
been shown to be successful in producing monoclonal antibodies (Spitz 
1986).
The dependence of the fusion specific efficiency on the number of 
specific B-cells in the spleen prompted the use of different ways to 
increase the number of the desired B-cells. The antigen can be 
adsorbed to a matrix, which is then injected in the host (Sternick and 
Sturmer 1984, Knudsen 1985). Splenocytes from immunized animal 
can be transferred into another X-irradiated animal, and the spleen of 
the second animal used for fusion (Siraganian et al., 1983). Selective 
reduction of response toward the determinants which are not of 
interest, is possible by using cytotoxic agents (Matthew and 
Petterson 1983), by passive immunization of the recipient with 
antibody directed toward the other determinants (Thalhamer and 
Freund 1985), by immunization with antigen-antibody complex 
(Eager and Kennett 1986) and by the blocking of unwanted deter­
minants by binding them with antibody, and the antigen antibody 
complex used for immunization (Foster 1982).
The selection of animals high titre of antibody in the serum for 
fusion does not always result in high specific fusion (Stahli et al., 
1983), and more important is the time between the boosting and the 
fusion. It was shown that the specificity of antibody produced as well 
as the fusion specific effeciency depend on the time between boosting 
and fusion, and has been found to be between three and four days. The 
repeated stimulation with a potential immunogen seems to reduce the 
initial response (Lee and Kohler 1974). However, high concentration of 
circulating antigen up to the day of fusion has been shown to be a 
prerequisite for successful fusion (Stahli et al., 1980).
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The properties of antibodies are known to be affected by the form 
and amount of antigen,the choice of adjuvant and the regimen of 
immunization. IgE antibodies were shown to be produced when alumi­
num hydroxj de gel was used as an adjuvant (Tung 1983, Levine 
and Vaz 1970), while the use of Freunds adjuvant supressesIgE 
antibody production (Tung et al., 1978). Oral administration of bac­
terial cell wall antigen (Morisaki et al., 1983) and long term adminis­
tration of antigen intravenously (Colwell et al., 1986) resulted in IgA 
antibody production. IgM antibody was usually obtainable by taking 
the spleen 3-4 days after the first immunization (Trucco et al., 1978).
1.3.1.2. In-vitro immunization
The exposure of dissociated spleen cells to an antigen in tissue cul­
ture is called in vitro immunization. Before the introduction of mono­
clonal antibody technique, in vitro immunization was used, and 
responses were demonstrated (Marbrook 1967, Mishell and Dutton 
1967). The cell culture conditions, from the viewpoint of antibody 
synthesis have been studied (Click et al., 1972).
Immediately after the introduction of monoclonal antibody 
techniques(Kohler and Milstein 1975), in vitro immunization has been 
applied to the production of monoclonal antibody. Since then this tech­
nique has been applied successfully for the production of monoclonal 
antibody to highly conserved proteins (Pardue et al., 1983) as well as 
many other antigens (Luben et al., 1982, Jonak and Kennett 1984). The 
application of in vitro immunization has been reviewed by Reading 
(Reading 1982, 1986).
Crucial importance of in vitro immunization lies in the fact that 
producing human-human hybridomas in the usual way is not ethically 
feasible. This technique can be also of particular value in the pro­
duction of monoclonal antibody to precious and rare antigens. Other 
advantages include, short immunization time, escaping the MHC con­
trol, circumventing the route of immunization problems and better 
chance of spleen cell size monitoring and control if needed. Finally,
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with the increased demand of human monoclonal antibody, it is at 
present the only method well-suited for this purpose.
1.3.2. Fusion partners
1.3.2.1. Murine myeloma cell lines
From the work of Kohler and Milstein (1975)it was indicated that, 
the successful marriage between normal spleen cell and immortal 
myeloma partner depend on the differentiation state of both cells, and 
the use of the same species myeloma cells enhances the chance of hybrid 
rescue.
A number of mouse myeloma cell lines have been used as 
fusion partners. The choice between the different myeloma partners 
depend on the fusion properties and the secretion and synthesis 
of immunoglobulin by the cells. Those cell lines which support the 
fast growth of their hybrids and do not produce and/or secrete 
antibody themselves are usually the best.
The majority of the commonly used myeloma cell lines are either 
of mouse (Balb/c) or rat (Lou/c) origin . The mouse cell lines are fre­
quently used both in mouse-mouse and cross-species fusions. Rat 
myeloma cell lines on the other hand are very seldom used. This could 
be due to the problems encountered in maintaining the cell line as well 
as the rat hybridoma (Samoilovich et al., 1987).
1.3.2.2. Human myeloma cell lines
The potential of human-human monoclonal antibodies is obvi­
ous, especially in therapy where the murine monoclonal antibodies 
usually stimulate the production of antibody when given in-vivo. In 
addition, human antibodies and/or autoantibodies can be used to pro­
duce anti- idiotypic antibodies, which will be useful in the study of 
immune system regulation (Kozbor and Roder 1983).
The production of human monoclonal antibody has been 
recently reviewed (James and Bell 1987). There have been several cell 
lines established as fusion partners, only few of these are myeloma
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and the rest are Epstein-Barr virus transformed cells. The murine 
myeloma cell lines are very successful fusion partners, the human 
myeloma cell lines in comparison grow very slowly and are rarely 
used.
The mouse-human fusion, though useful did not eliminate the 
sensitization problems encountered in in vivo use of antibody. 
Furthermore, the resulting hybridomas are not stable due to 
chromosomal loss shortly after fusion. One way to circumvent this 
problem is using the mouse-human hybrid as fusion partner (James 
and Bell 1987), and the same principle can be used to improve the 
growth characteristics of human myeloma lines (Kozbor et al., 1984).
Despite the existence of a number of human myeloma cell lines, 
none of them offer any advantages over others in terms of fusion fre­
quency and cloning efficiency. Nonetheless, the unabated research no 
doubt will result in better myeloma cell lines. The murine and human 
myeloma cell lines available for fusion are shown in table 1.2.
1.2.3. Fusogen
There are many ways to fuse cells and membranes; some are 
effective, others not. Spontaneous cell fusion is known to occur at a 
very low level, therefore, chemical, viral and electrical methods were 
developed to accelerate the fusion.
Fusion of many biological materials is easy to accomplish with 
any of the above mentioned methods, but the viability and the survival 
of the cells or the fused material is important as much as the fusion. In 
the field of hybridoma production, different methods were applied 
with different degrees of success, they include virus, PEG and 
electrofusion. Laser cell fusions have been shown to be effective, 
but they need expensive equipment which is beyond the capability of 
most laboratories.
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Table 1.2
Myeloma cell lines used for hybridoma production
Species Cell line Ig secreted Selectable marker References
Mouse
P3-x63-Ag8.653 - HPRT- Kearney et al., 1979
SP2/0-Agl4 - HPRT- Shulman et al., 1978
FO - HPRT-
.
Fanekas de st.Groth and Scheidegger 1980
S 194/5XX0.BU.5 - TK- Trowbridge 1978
FOX-NY - APRT-,HPRT- Taggart and Samloff 1983
Rat IR983F - HPRT- Bazin 1982
Y3-Ag 1.2.3 K HPRT- Galfre et al., 1979
Human
SKO-007 E/C HPRT- Olsson and Kaplan 1980
GM-1500 6TG-2 v2/C HPRT- Croce et al., 1980
KR-4 v/C HPRT-fOua Kozbor et al., 1982
LICR-LON-HMy2 vl/C HPRT- Edwards et al., 1982
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1.3.3.1. Virus fusion
Viruses of the RNA-containing lipid-envelope type are most com­
monly employed in cell fusion. The presence of specific receptor on 
the cells is thought to be essential for the binding of fusogenic 
viruses (Okada 1969). However, Sendai virus has been found to bind 
artificial membranes without receptors (Haywood 1974), and the Sam- 
liki Forst Virus (SFV) infects cells lacking histocompatibility 
antigen (Helenius et al., 1980).
The chemical structure of the viral spike glycoproteins and the 
lipid composition of the cell membranes are of critical importance 
(Gallaher et al., 1973, Gething et al., 1978, Fries and Helenius 
1979), while temperature and pH are not very important in fusion 
(Okada 1969, Foster 1982).
Different types of viruses were used in cell fusion, to induce con­
tinuous synthesis of specific antibodies. Simian virus was used to pro-
/
duce antibody to type III pneumococcal polysaccharides (Strosberg et 
al., 1974), Abelson virus was used to transform mouse lymphocytes 
to Ig-producing lines (Abelson and Rabstein 1970), Epstein Barr virus 
was used to transform human lymphocytes (Fahey et al., 1966). Since 
then several lines have been established secreting antibodies to 
acetylcholine receptor (Kamo et al., 1982), phosphorylcholine (Yoshie 
and Ono 1980), bacterial and viral antigens (Rosen et al., 1983, 
Crawford et al., 1983, Seigneurin et al., 1983), haptens (Steinitz et al., 
1977, Kozbor et al., 1979) and rheumatoid factor (Steinitz et al., 
1980, Steinitz et al., 1982).
Despite the success of viruses in transforming cells, and pro­
duction of specific antibodies, it appears that the amount of anti­
body secreted is relatively small and the lines established lose their 
ability to produce specific antibody in vitro after long term culture 
(Kozbor and Roder 1981, Crawford et al., 1983). Viral cell fusion 
was also found to be low (Yelton et al., 1981) and standard 
preparation is needed for long term success (Pentecorvo 1975).
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1.2.3.2. Polyethylene glycol (PEG)
PEG was first applied to somatic cell hybridization by Pon- 
tecorvo (Pontecorvo 1975) after it had been shown to fuse plant cells 
(Kao and Michayluk 1974). The precise mechanism by which PEG 
promote cell fusion is not known, although during the initial stages 
of hybridization structural changes in membrane were observed 
(Knutton and Pasternak 1979), and membranes were found to make a 
contact.
PEG as well as its commercial contaminants are necessary for 
fusion. The removal of these impurities render PEG non- fusogenic 
over 1 minute cellular exposure (Westerwoudet 1985), and purified 
PEG was found to fuse hen erythrocytes over 15 minute exposure. The 
fusion is enhanced at least to a lesser extent by the inclusion of DMSO 
in PEG solution (Norwood et al., 1976, Fazekas de st. Groth and 
Scheidegger 1980).
Although PEG is toxic to cells at high concentrations, 30 to 55% 
w /v  were usually used to fuse cells, with the fusion optimum being at 
50%. High and low molecular weight grades of PEG can be used in 
fusion, the most common two were 1500 and 4000 molecular weight. 
The fusion efficiency has been shown to be affected by the molecu­
lar weight, the manufacturer and even the lot number (Davidson et 
al., 1976, Fazekas de st. Groth and Scheidegger 1980, Goding 1983).
1.2.3.3. Electro-fusion
This technique has been in use for sometime for the fusion of plant 
cells. More recently it was developed and applied to the production of 
murine and human monoclonal antibodies (Zimmermann et al., 1982, 
Zimmermann et al., 1985, Vienken and Zimmermann 1982, Bischoff et 
al., 1982).
The electro-fusion depends on the establishment of close contact 
between cell membranes by the action of electrical force, and an intense 
electrical field pulse of short duration to trigger the fusion between 
adjacent cells.
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This technique offers many advantages over the other two common 
methods. Fusion of pairs of cells is possible, it permits immediate 
cloning of fused cells and it gives high fusion efficiency. However, 
despite these advantages this method requires expensive equipment, 
it is cumbersome as only a few cells are handled each time. Hence the 
technique cannot be used to the full unless the steps are automated 
and the equipment is available at a lower price.
1.3.4. Hybridization
1.3.4.1. Selection
Considering the low percentage of cells fused, the newly formed 
hybrids have to be protected and well cared for. The fact that fusion 
mixtures contain three different types of cells and only one type is 
desired, necessitate selection if the hybrids are to survive. The spleen 
cells usually die within a week,so they do not pose a threat to the 
hybrid cells. Myeloma cells on the other hand will not die in normal 
media and have to be selected.
The selection of the desired cells is achieved by the continuous 
selection of myeloma cells in media containing metabolic poisons such 
as 8-azaquanine and 6-thioquanine. The cells grown in these selec­
tion media develop a deficiency in enzymes important for the synthesis 
of DNA and RNA by the salvage pathway. Therefore, when grown in 
media containing a blocker for the de novo pathway they die.
The commonly used system was the hypoxanthine- 
aminopterin- thymidine (HAT) selection system devised by Littlefield 
(1964). The myeloma cells are made deficient in the enzyme hypox- 
anthine phosphoribosyltransferase (HPRT) or thymidine kinase (TK) 
by growing them in 8-azaquanine. Those surviving in 8-azaquanine 
lack HPRT or TK enzymes and depend on the de novo synthesis of 
nucleotide precurors for nucleic acid synthesis. This de novo pathway 
is blocked by the addition of aminopterin to the media.
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1.3.4.2. Fusion protocols
Many fusion protocols have been used in hybridoma production 
(Goding 1986). Only minor modifications were introduced to the origi­
nal technique (Galfre et al., 1977), but the essentials were the same.
Improvements in the fusion efficiency seem to be dependent on the 
type of myeloma cell line, and the type and concentration of PEG. The 
duration of exposure seems to be around one minute, although in a 
recent study it was found to be less. The pH of the PEG solution has 
been shown to be important (Sharon et al., 1980), and the optimal was 
found to be between pH 8-8.2. Temperature, cell number and the 
ratio of spleen cells to myeloma cells seem to be of less importance 
(Goding 1986).
1.3.4.3. Feeder layer
Unknown factors support the growth of hybrids and single cell 
during cloning; these factors have been provided by the addition of 
peritoneal macrophages (Fazakas de st.Groth and Scheideggen 1980), 
splenocytes (Goding 1986), thymocytes (Oi and Herenberg 1980) 
and human endothelial culture supernatant (Astaldi 1983) to the 
fused or cloned seeded cells. The addition of cells which provide the 
growth factors although supporting the growth of cells, may act as a 
source of contamination. Feeder layer cells may kill or select the grow­
ing hydrid cells either by exhustion of media nutrients on which the 
hybrid live or secretion of toxic materials which kill the hybrids.
The use of alternatives, like macrophage-conditioned media have 
been shown to support the growth of plasmacytoma cells (Nordan 
and Potter 1986) and hybridoma cloning (Rathein and Greczy
1986). In mouse-rat fusions, T-cell-derived lymphokines were 
shown to be essential for the growth of the resulting hybrids (Van 
Snick et al., 1986).
The development of defined additives could lead to serum free 
media used in all stages of cultivation (Samoilovich et al., 1987).
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1.3.4.4. Production of monoclonal antibody in-vivo
The injection of hybridoma cells into the peritoneal cavity for the 
in vivo production of monoclonal antibody is a common practice. It is 
fast, needs only 2 weeks for the ascitic fluid to accumulate in the peri­
toneal cavity, and yield a concentrated antibody sometimes up to 50 
mg/ml of ascites (Samoilovich et al., 1987). The mice normally 
prepared by injection of 0.5 ml prestain (2,6,10,14- 
tetramethylpentadecane ) intraperitoneally 7 days before the cells 
injected into the mice, and two to three weeks afterward ascitic fluid is 
collected. However, the production of antibody in-vivo, without prior 
preparation of mice is also possible (Samoilovich et al., 1987), and the 
use of adjuvant instead of prestain was shown to decrease the prepara­
tion time with no loss in antibody activity or decrease in ascites 
volume.
The only obstacle is that the cells should be compatible with 
that of the host, although suppression of the immune system by 
immune suppressive drugs or X-irradiation is used for the non­
compatible cells. The passage (Truitt et al., 1984, Kozbor et al., 
1985) and growth of cells in liver tissue (Hirsch et al., 1985) enhance 
their stabilization and secretion.
The antibody produced in vivo may not be suitable for use in 
therapy, and its purification and treatment could change its 
characteristics. Moreover, purification was shown to reduce the yield 
with each step (Dalchau and Fabre 1982, Bazin et al., 1984).
1.3.4.5. Production of monoclonal antibodies in-vitro
Hybridoma cells are originally grown in-vitro. The concentration 
of antibody is low compared to in vivo production. However, in 
many applications highly purified antibody is needed. In both in vivo 
and in-vitro systems the antibody is contaminated with complex mix­
tures of proteins and contain many unknown components. Hence, cells 
were grown in synthetic serum free media to ease the purification 
(Clevdand and Erlanger 1983, Kovar and Franek 1984). The growth
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of cells as well as the increase in antibody production were of prime 
importance in the in-vitro production of antibody. From the commer­
cial point of view in vivo production of antibody is not a feasible pro­
position. Many additives to the media were used to support the 
growth and increase the antibody production with claimed successes. 
These include different proteins, hormones, growth factors, and mix­
tures of all (Chang et al., 1980, Darfler and Insel 1982).
The large scale needed for the commercial viability of antibody 
production necessitates the development of many devices where large 
numbers of cells can be cultivated, and large amounts of antibody 
obtained daily. The cells have been grown in many devices depending 
on the resources and needs, ranging from an ordinary T-flask, to fer- 
minters , hollow fiber devices and microencapsulation (Galfre and 
Milstein 1981, Fazekas de st.Groth and Scheidegger 1980, Hopkinson 
1985, Grinda and Jarvis 1984, Scheirer et al., 1984).
Some of these techniques are being exploited currently for in 
vitro production of monoclonal antibodies by many commercial institu­
tions, and adapted as routine practice for the cultivation of many 
chosen cell lines. There are even claims that the antibody concentration 
in vitro may have reached the corresponding in vivo levels.
1.4. PARATHYROID HORMONE
1.4.1. Biosynthesis and secretion
The 84 aminoacid PTH polypeptide arises from a larger precursor 
of 115 amino acids PrePro-Parathyroid hormone (PreProPTH) by 
two successive cleavages of small amino-terminal sequences (Habener 
and Kronenberg 1978, Habener and Potts 1978 and Habener et al.,
1978). According to the ’signal’ hypothesis (Blobel and Dobberstein 
1975 ) the leader sequence of PreProPTH passes through the mem­
brane of the endoplasmic reticulum whilst translation of the growing 
peptide chain continues behind it. Within the rough endoplasmic 
reticulum the first 25 amino acids are then cleaved to form Pro­
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parathyroid hormone (ProPTH). In the golgi complex the other six 
amino acids cleaved resulting in the formation of parathyroid hor­
mone (PTH) ( Habener et al., 1979) Secretion of the hormone seems 
coupled in someway to synthesis as only small amounts of PTH 
were stored in the gland. The PTH structure is shown in figure 1.3, 
and the synthesis and secretion is shown in figure 1.4.
Calcium surprisingly appears to have small or no effect on the 
conversion of ProPTH to PTH (Habener et al., 1975), although 
paradoxically it is the major regulator of parathyroid activity and 
expected to have some effect on the rate of PTH synthesis. High extra­
cellular calcium concentration stimulates and low concentration 
inhibits the degradation of PTH within the parathyroid gland 
(Habener et al., 1975). The stimulation and inactivation of chief cells 
of the parathyroid gland to synthesize PTH is affected by hypo and 
hypercalcaemia respectively. Recent studies have shown that some PTH 
is stored in granules and released by exocytosis (Habener et al., 1979) 
though contrary to other secretory cells, where exocytosis is 
stimulated by calcium,PTH secretion is inhibited (Brown et al., 
1980 and Habener et al., 1976). The preferential and rapid release of 
PTH in response to stimuli suggested the direct synthesis and tran­
sport of PTH to the periphery of the cell without packaging (Mac Gre­
gor et al., 1975 and Morrissey and Cohn 1979).
Cyclic AMP (cAMP) is evidently involved in the secretion of PTH. 
Adenylate cyclase activity is inhibited by calcium and it is present in 
parathyroid gland . cAMP concentration has been found to be 
increased in parallel with PTH secretion caused by 
adrenaline,isoprenaline, dopamine, secretin, prostaglandin E2 and 
hypocalcaemia (Blum et al., 1978, Brown et al., 1980, Brown et al., 
1979, Brown et al., 1977, and Gardner et al., 1978). Decreased con­
centration of cAMP was also noted with agents suppressed PTH secre­
tion such as a  -adrenergic agonists (Brown et al., 1978) and prosta­
glandin F2 a  ( Grander et al., 1978). Studies of dibutyryl cyclic 
AMP and other inhibitors of phosphodiesterase in vitro caused increased
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Figure 1.3: The structure of human parathyroid hormone. 
The structure of bovine and porcine PTH is shown with the 
positions indicated above and below the human structure. 
(Adapted from Keutmann et al., 1978).
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Figure 1.4: The proposed intracellular pathway of the 
biosynthesis of parathyroid hormone. Pre-Pro-Parathyroid 
hormone (Pre-Pro-PTH), Pro-Parathyroid hormone (Pro­
PTH). The time needed for these events to occur is given 
below the scheme. (Adapted from Amaud 1983).
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PTH secretion
The calcium concentration in the blood profusing the gland has 
been found to be inversely related to PTH concentration in vivo and 
in vitro ( Habener and Potts 1976) using bioassay and radioimmunoas­
say. However, the relation between PTH secretion and plasma calcium 
is not a simple one; mild hypocalcaemia initially produces a steep 
increase in the rate of secretion , which becomes maximal and 
remains so with increased hypocalcaemia. The inverse relationship 
also exists between magnesium concentration and the rate of PTH 
secretion both in vivo and in vitro ,but it is two to three times less 
potent on a molar basis (Habener and Potts 1976). Therefore,compared 
to calcium, magnesium contribution to PTH release is small under phy­
siological conditions. However, very low concentrations are associated 
with reversible failure of PTH secretion (Anast et al., 1976 )
The relationship between Vit D and PTH secretion is not very easy 
to establish, a number of studies intended to clarify the relationship 
gave conflicting results. 1,25-DHCC has been shown to have no effect 
(Hurst et al., 1979), to stimulate (Canterbury et al., 1978) or to 
suppress (Chertow et al., 1975, and Dietel et al., 1979) the 
secretion of PTH in vivo (Canterbury et al., 1978, and Hurst et al., 
1979) and in vitro (Dietel et al., 1979). 24,25-DHCC was reported to 
have no effect (Dietel et al., 1979) and suppress PTH secretion (Canter­
bury et al., 1978, and Care et al., 1976), and 25,26-DHCC reduced 
PTH secretion (Care et al., 1978).
Catecholamines, according to some evidence, are involved in PTH 
secretion. PTH release was found to be stimulated by beta adren­
ergic agonists (Kukreja et al., 1976, and Williams et al., 1977). The 
specific receptors on parathyroid cell are of the B-2 subtype, and 
isoprenaline stimulates PTH release and cAMP production greater than 
noradrenaline (Brown et al., 1977). The PTH secretory response to 
hypocalcaemia has not been modified when the effect of adrenaline 
was inhibited by propranolol (Blum et al., 1978, and Brown et al.,
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1978) indicating the dissociation of the two receptor response sys­
tems. Adrenergic agonists augment secretion when the secretory 
route is already high (Blum et al., 1978, and Mayer et al., 1979) but 
have little or no effect during normocalcaemia.
1.4.2. Heterogeneity and metabolism
The interpretation of PTH immunoassay results has been 
complicated by the heterogeneity of circulating PTH (Berson and 
Yalow 1968,and Habener and Segre 1979). Intact hormone (molecular 
weight 9500 daltons) is the main form secreted by the glands. Other 
fragments may also be secreted especially during hypercalcaemia ( 
Mayer et al., 1979). Biologically inert carboxy terminal PTH fragment 
(molecular weight 7500 daltons) has been demonstrated in large 
quantities in the serum and significant quantities of biologically active 
amino-terminal (molecular weight 4000 daltons) moiety has also been 
detected ( Segre et al., 1977). Most of the immunoassays used will 
measure carboxy terminal fragments (D’Mour etal 1979), intact hor­
mone and small quantities of amino terminal peptides 1-34 or 
1-36 (Hunziker etal., 1977).
The cleavage of the hormone to carboxy terminal and amino 
terminal fragments may be a form of degradation or activation of the 
hormone prior to receptor binding (Segre et al., 1981). However, the 
cleavage of intact hormone has been suggested to be not necessary for 
the expression of full biological activity in bone and kidney 
(Goltzman 1978).
The half life of the fragments may determine the hetero­
geneity of PTH in serum. The amino terminal fragment has a half 
life of 2-5 minutes the shortest, while that of carboxy terminal pep­
tide may be in hours (Segre et al., 1976, Flueck, et al., 1977, Habener 
et al., 1976, and Hunziker et al., 1977). The metabolism in the peri­
phery mainly liver, kidney and bone is the main source of hetero­
geneity under normal homeostasis. Liver selectively takes up intact 
hormone but not amino or caboxy terminal fragments (Martin et al.,
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1979); this uptake was demonstrated in dog, rat, chicken and humans 
in vivo and in vitro (Martin et al., 1979), with the hypocalcaemia 
accelerating the process.
The kidney may act as the source of heterogeneity, especially in 
hypocalcaemia (Hruska et al., 1977, and Hanono et al., 1978) as well 
as removing the intact hormone and fragments from the circulation. 
The carboxy terminal fragments are removed by glomerular 
filtration and tubular reabsorption (Martin et al., 1979), and the 
intact hormone and amino terminal fragments are removed by peri­
tubular uptake and also by glomerular filtration with subsequent 
peroximal tubular reabsorption. The high value of serum carboxy ter­
minal PTH assays in chronic renal failure patients (Freitag et al., 1978) 
indicate impaired glomerular filtration. The degradation of PTH by 
the liver and kidney is responsive to serum calcium level (Kleeman 
and Kleeman 1979) and there is a weak positive correlation between 
serum calcium and metabolism of PTH in the kidney but not in the 
liver or the limb.
Bone metabolizes the intact hormone with the release of carboxy 
terminal fragments and complete degradation of amino terminal 
fragments, indicating the contribution of skeletal metabolism of PTH 
to the heterogeneity of circulating fragments. Intact PTH stimulate 
renal cortical membrane, adenylate cyclase in fetal rabbit bone 
(Goltzman 1978), and fetal rat and isolated bone cells (Freitag et al.,
1979). The 24-48 peptide which is a competitive inhibitor to PTH 
degradation has been found not to inhibit renal cortical adenylate 
cyclase activation by the intact hormone (Resenblatt et al., 1977). 
Moreover, the amino terminal fragment (1-34) but not the intact 
hormone were found to be extracted by dog tibia (Martin et al.,
1978), and cAMP production was stimulated with the amino terminal 
fragment 1-34 but very little with intact hormone. Perifusion of cat 
limb bone and hen femur with PTH shows no calcium mobilization 
from bone..
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1.4.3. Physiology of PTH
The principal target tissues where PTH has a direct effect are kid­
ney and bone.
In the kidney, early studies showed PTH to produce a phospha- 
turic effect which was later found to be the result of impurities 
affecting the renal dynamics. Improved laboratory procedures and the 
availability of highly purified parathyroid hormone demonstrated 
that PTH decreased phosphate reabsorption in proximal and distal 
tubules causing phosphaturia ( Pastoriza et al., 1978). Phosphate tran­
sport paralleled closely that of sodium in proximal tubule under the 
influence of PTH. Some suggest that PTH, through regulation of 
sodium reabsorption, indirectly modifies phosphate reabsorption in 
the proximal tubule; according to others they are dissociated. PTH 
adminstration increases bicarbonate excretion which is largely due to 
decreased proximal tubular reabsorption.
After PTH administration the urinary excretion of calcium was 
decreased via complex actions on renal tubules. Calcium reabsorption is 
enhanced in the thick limb of Henle’s loop (Bourdean and Burg
1979), in the distal convoluted tubule and the cortical collecting 
ducts (Agus et al., 1975 and Shareghi and Stoner 1978) but inhibited 
in the proximal tubule. The full expression of the hypocalcaemic 
effect of thiazide diuretics requires PTH ( Parsons 1976), and PTH 
adminstration reduces magnesium excretion. Primary hyperparathy­
roidism patients have high rates of magnesium excretion even 
though they may be hypomagnesaemic which can be explained by 
the overriding of the retentive effect of PTH and inhibition of mag­
nesium reabsorption.
One of the important actions of PTH on the kidney is to stimulate 
the conversion of 25-hydroxycholecalciferol to the active hormone 
1,25-dihydroxycholecalciferol through its effect on renal 1 a  -  
hydroxylase enzyme. It is also shown that primary hyperparathy­
roidism patients have higher levels of 1,25-DHCC than normal
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subjects (Haussler etal., 1976).
The mechanism of action of PTH on the kidney has been studied 
with a combination of methods. It activates adenylate cyclase 
through its binding to cell surface receptors. Early studies were ham­
pered by PTH iodination problems, as chloramine T is thought to pro­
duce some damage which renders the hormone biologically inactive. 
Hence, later studies used PTH labelled with 125 I using lactoperoxidase 
method ( Health and Aurbach 1975 ) or 15Semethionine or ?H  -tritium 
(Zull et al., 1977). PTH receptor was suggested to be a single high 
affinity site present in relatively high concentration (Nissenson and 
Arnaud 1979). The binding of PTH to its receptor was not affected 
by many peptides, but was displaced by insulin in some studies and 
inhibited by high concentrations of ACTH in others (Zull et al.,
1977).
PTH generated cyclic AMP is thought to activate cytosolic and 
membrane bound kinases (Kinne et al., 1975). Both cyclic AMP and 
PTH increase the permeability of proximal tubules ( Lorentz 1976 
and Puschett et al., 1976). Cyclic AMP or dibutyryl cyclic AMP 
were shown to cause phosphaturia in the dog, rat and man . Cyclic 
AMP were shown to mimic PTH in decreasing proximal tubular 
reabsorption of phosphate and sodium in the dog and r a t .
While phosphate reabsorption was shown to be inhibited by cyclic 
AMP, dibutyryl cyclic AMP and PTH (Goldberg et al., 1976), cyclic 
AMP and its analogue dibutyryl cyclic AMP were mimicking some or 
all the effects of PTH on the renal tubules. They cause decrease in 
fractional excretion of calcium (Burnatowsk et al., 1977), reduce 
calcium reabsorption in proximal tubule, increase calcium reabsorption 
in the cortical thick ascending loop of Henle (Bourdean and Burg
1979), and the distal convoluted tubule (Costanzo and Windhager
1978). Thus the action of PTH on the kidney is mediated by cyclic 
AMP.
In bone, PTH inhibits bone formation ( Parsons 1976, Raisz
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1977 and Raisz et al., 1978), and its osteolytic action was found to 
be inhibited by a diffedency of many steroid hormones, caldtonin 
and vitamin D (Atkins and Peacock 1975, and Raisz 1977). PTH is 
also shown to have an anabolic action on bone (Parsons 1976, and 
Herrman-Erlee 1976). Bone formation is also accelerated by low 
doses of synthetic human PTH (1-34) in animals (Hafti et al., 1982), 
and to increase bone mass in man (Reeve et al., 1976). Bone cyclic 
AMP (Heerche et al., 1978, and Smith and Johnson 1975),as well as 
tissue cyclic AMP, all rise after exposure of bone to PTH having bone 
cyclic AMP peaking within thirty minutes. The rise reaches thirty  to 
fourty fold with large doses of PTH in rat (Nogata et al., 1975) but 
not in man (Tomlison et al., 1975). Some or all actions of PTH on 
bone are mediated by cyclic AMP. In rats cyclic AMP and dibu­
tyry l cyclic AMP were shown to increase urinary excretion of pep- 
tidyl hydroxyproline. In bone cell culture in vitro cyclic AMP and 
dibutyryl cydic AMP was shown to mimic PTH action by inducing 
bone resorption and enhancing lactate, citrate and lysosomal enzyme 
formation. However, the effects of dibutyryl cyclic AMP differ from 
that of PTH as the effects are produced only at high concentration and 
only after a long delay, and in addition it antagonizes PTH over a 
wide range of concentrations.
PTH regulates caltium flow from the bone to the extracellular 
fluid by direct interaction with the bone (Talmage and Mayer 1976). 
Mineralization and bone matrix formation were found to be inhibited 
and bone resorption and cacium release were stimulated with high doses 
of PTH (Raisz 1976). PTH is also shown to increase hyaluronate 
synthesis (Severson 1978), and to inhibit citrate decarboxylation 
and collagen synthesis (Dietrich et al., 1976). The effectors of PTH- 
induced bone resorption is believed to be the multinucleated osteoclasts. 
Mononucleated cells may also contribute to bone resorption (Mundy et 
al., 1977, Kahn et al., 1978 and Galasko 1976). The effects of PTH on 
osteoclasts starts with an increase in RNA synthesis, raising the 
number of nuclei per osteoclast (Addison 1980) and the increase in
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osteoclast number (Fallon et al., 1981).
The stimulatory effect of PTH on the lysosomal enzyme system 
has been studied using histochemical methods and enzyme assays of 
bone medium (Eilon and Raisz 1978). It shows a correlation between 
the stimulation of enzyme activity and relase of radiolabelled calcium 
from bone. PTH also inhibited osteoblast activity; it decreases the 
synthesis of collagen by bone (Dietrich et al., 1976 and Kream et al.,
1980) and by osteoblastic osteosarcoma cells (Kream and Majeska
1981). PTH also decreases citrate decarboxylation. Organ cultures 
have contributed much to the current understanding of the 
final physiological effects of PTH. Among the currently used models 
are; neonatal tissue subjected to enzymatic digestion ( Peck et al., 
1977, Smith et al., 1975, Rao et al., 1977, Chen and Feldman 1978, 
Wong and Cohn 1975, Nijweide and Van der Plas 1979 and Pliam et 
al., 1981) and normal and abnormal cells derived from osteosarcomas 
(Majeska et al., 1978 and Martin et al., 1976). The target cells for 
PTH in bone is illustrated by the presence of PTH specific receptors. 
Binding of biologically active .125/  -PTH to osteoblasts and pre­
osteoblasts in chicken calvaria (Slive et al., 1981) and in chicken 
bone cells (Pliam et al., 1981) are in agreement with the bioassay 
results from mouse bone cells (Smith et al., 1975, Rao et al., 1977, 
Wong and Cohn 1975 and Peck and Kohler 1981) and osteosarcoma 
cells (Majeska et al., 1978 and Martin et al., 1976) in which PTH eli­
cited large increases in cellular cAMP content and rapid morpholo- 
giocal changes (Miller et al., 1976 and Jones and Boyde 1976). The 
large increase in cAMP seen in PTH treated bone cell studies suggest 
that it largely comes from the osteoblasts, as it correlates with activa­
tion of cAMP dependent kinases (Portridge et al., 1981).
Calcium is required for the action of PTH in the kidney 
(Rasmussen et al., 1976) as well as in bone (Wong et al., 1978). Cal­
cium may affect PTH action through changing the conformation of 
the receptor on the cell surface (Chen et al., 1980 and Zull et al., 1976) 
or regulating adenyl-cyclase-associated calmodulin activity (Peck
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and Kohler 1981). PTH-treated bone is shown to increase calcium 
uptake (Dziak and Stern 1975). However, calcium entry to the cells 
(OB cells) may be a direct result of PTH binding, as PTH induction of 
cAMP and calcium uptake may be unconnected (Chen et al., 1980). 
Moreover, neither cAMP nor l,25(OH)2 D3 is shown to increase bone 
cell calcium uptake (Dziak 1978). Thus there may be two mediators 
of PTH action on bone , normally cAMP and calcium.
The calcium inophore A23187 has been shown to stimulate cal­
cium release from bone at the appropriate concentration (Dziak and 
Stern 1975) and the calcium channel blocker verapamil inhibits PTH 
effect on bone (Herrman-Erlee et al., 1977). However, the ability of 
PTH to increase cyclic AMP and calcium entry to the target cells is 
shown to be dissociated (Dziak and Stern 1975).
PTH has been shown to have anabolic effects on bone. Prolonged 
treatment with low concentration of PTH has been found to enhance 
bone formation in vivo , and the same was observed with the 1-34 bio­
logically active fragment in vitro (Herrman-Erlee et al., 1976) mimick­
ing the in vivo action of the 1-84. There is evidence that 1-34 fragment 
is generated in vivo but has not been found when bPTH(l-84) was 
incubated with bone cells or bone (Freitage et al., 1979). Thus it 
seems that the effect of PTH on bone is dose dependent (Majeska and 
Rodan 1981).
Several studies have demonstrated the binding in vitro of labelled 
PTH to normal plasma membrane of chicken (Chansel et al., 1977, 
and Nisseneon and Amaud 1979), rat (Rosenblatt et al., 1976), cow 
(Zull et al., 1977), dog (Segre et al., 1979, and Bellorin et al., 1981) 
and man (Abbott et al., 1981). The biological significance of this has 
been attributed to PTH binding sites if they appear to be coupled to 
activation of adenylate cyclase, since physiological effects are not 
demonstrable.
cAMP play an intermediary role in PTH induced inhibition of renal 
phosphate reabsorption ( Burnatowska et al., 1977),PTH stimulation
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of distal tubular calcium reabsorption ( Burnatowska et al., 1977) 
and l,25(OH)2D vitamin D3 production (Horiuchi et al., 1977). Some 
evidence shows that renal adenylate cyclase system is equally sensi­
tive to PTH in vitro versus in vivo (Nissenson et al., 1980). PTH bind­
ing sites have been shown in solubilized bovine cortical plasma mem­
branes (Malbon and Zull 1977) and found to be >  100,000 daltons by 
gel filtration.
bPTH(l-84) and (1-34) were reported to have similar potencies in 
stimulating renal adenylate cyclase (Nissenson and Arnaud 1979 and 
Nissenson et al., 1981) while only bPTH(l-34) increased cyclic 
AMP production in isolated perfused canine bone, but not 
bPTH(l-84) (Martin et al., 1978).
1.4.4. Structure function relationship
Dark-field electron microscopic study (Fiskin et al., 1977) and a 
theoretical study of PTH secondary structure (Zull and Lev 1980) 
suggest a structure consisting of two stabilized spherical clusters 
linked by a straight chain region.
In many assay systems synthetic bPTH(l-34) behave identically 
to PTH(l-84) isolated from natural sources (Parsons et al., 1975, Segre 
et al., 1979, Herrmann-Erlee et al., 1976, Herrmann-Erlee et al., 
1978, Neuman and Schneider 1980 and Bringhurst and Potts 1981). 
However, in many others the synthetic bPTH(l-34) was shown to 
be less active than the native hormone (Herrmann-Erlee et al., 1976, 
Bringhurst and Potts 1981, Martin et al., 1980, Herrmann-Erlee et al., 
1980 and McGowan et al., 1981). In many assays these differences 
could be attributed to greater stability of the 1-84 possibly due to 
resistance to proteolytic influences (Herrmann-Erlee et al., 1978 and 
Bringhurst and Potts 1981).
The removal of the amino acids from the carboxy terminal of the 
PTH(l-34) leads to a decrease in binding affinity and hence in 
activity (Segre et al., 1979). However, in sensitive bioassays fragments 
as small as 1-26 sequence are found to bind and activate PTH receptors
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at high concentrations (Martin et al., 1980 and Goltzman et al., 
1978) whereas the peptides with 1-25 sequence or smaller show no 
binding or activation.
The removal of the amino terminal residues from bPTH(l-34) 
has been shown to drastically reduce the bioactivity ( Herrmann-Erlee 
et al., 1976 and Goltzman et al., 1978). bPTH(3-34) is a competitive 
inhibitor of PTH action( Herrmann-Erlee et al., 1976 and Goltzman et 
al., 1978), and thus the structure 3-34 has all the binding require­
ments, while position 1 and 2 are essential for the activation of the 
receptor. The replacement of the carboxy terminal 34 of PTH(l-34) 
leads to an increase in biological activity (Parsons et al., 1975, and 
Martin et al., 1981). The substitution of phenylalanine in position 34 
in bPTH(l-34) was found to be very useful in iodinating the frag­
ment with no loss of biological activity (Rosenblatt and Potts 1977, 
Goltzman et al., 1975 and Rosenblatt et al., 1976). The oxidation of 
methionine-containing species and analogues of PTH results in loss 
of binding affinity and inactivation of the hormone (Martin et al., 
1981, Rosenblatt et al., 1976, Coltrera et al., 1980, and Goltzman et al., 
1975). The substitution of methionine with norleucine in position 8 
and 18 resulted in a small decrease in biological activity in vitro 
(Rosenblatt and Potts 1977, Goltzman et al., 1975 and Chen et al.,
1980),concomitant tyrosinamide substitution in position 34 resulted in 
increase in activity in vitro, and the 3-34 analogue was a power­
ful antagonist at equimolar concentration (Rosenblatt et al., 1976 and 
Rosenblatt et al., 1977). The norleucine substitution leads to a 
decrease in biological activity in vivo (Rosenblatt et al., 1981). The 
substitution of valine in position 2 with D-valine resulted in total 
loss of biological activity (Coltrera et al., 1980 and Rosenblatt et al.,
1981).
Human hormone and its fragments were shown in the early in 
vitro studies to be less active than the corresponding bovine 
sequence peptides (Goltzman et al., 1975). In the PTH molecule posi­
tion 1 and 2 are associated with activation of the receptors and
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biological activity. The bovine hormone contains alanine in position 1 
whereas the human hormone has serine there, and exchange of posi­
tion 1 between the two hormones showed that the difference 
between the two hormones is totally due to the amino acid in position 
1 (Zull and Lev 1980, Parsons et al., 1975, Goltzman et al., 1978, 
Goltzman 1975 and Tregear and Potts 1975). In comparing hPTH(l- 
34) and bPTH(l-34) in vitro using the renal plasma membrane model 
system from various species, hPTH(l-34) was found to be less active 
in most cases (Goltzman et al., 1975 and Martin et al., 1975).
The hormone-degradative activity seems to be different among 
animal species, dependent on the assay tissue. hPTH(l-34) was inactive 
in the rat system where the degradative activity is high (Neuman and 
Schneider 1980 and Goltzman et al., 1975) and equipotent with 
bPTH(l-34) in the chick where PTH-active peptidases are low (Martin 
et al., 1975). It was also shown on the basis of chick hypercalceamia 
assay that PTH fragments which where less active in vitro were 
equipotent with the 1-84 sequence in vivo (Parsons et al., 1975, and 
Neuman and Schneider 1980). The 1-D-alanine substitution which 
leads to loss of activity in vitro resulted in increased activity in vivo. 
In various systems bPTH(3-34) analogue was found to be a weak 
antagonist of PTH in human giant cell tumors of bone, (Goldring et 
al., 1979, Ausiello et al., 1980 and Goldring et al., 1981) in embryonic 
calvarial systems (Herrmann-Erlee et al., 1980) and in skin fibroblast 
system (Goldring et al., 1979).
1.4.5. Measurement of parathyroid hormone
Parathyroid activity was measured by rat bioassays and various 
in vitro bioassays . However, these assays lack the sensitivity to 
detect the small quantities of hormonal activity in serum. Comple­
ment fixation assay was also used to measure PTH activity. 
Although it is not sensitive enough to measure PTH activity in serum, 
it was found useful in studying immuno-chemical changes in the PTH 
molecule, and it is the first assay to detect PTH-like agents in non­
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parathyroid neoplasms associated with hypercalcaemic syndrome.
The purification of the hormone, and the confirmation of amino- 
acid sequence led to the development of PTH assays. Until the 
introduction of radioimmunoassay, the measurement of PTH in serum 
was not possible. The first radioimmunoassay for PTH was described 
by Berson in 1963 (Berson et al., 1963). With the improvement in 
the bioassays, later generations of such systems were also capable of 
measuring PTH in serum.
The introduction of multi-channel analyzers in clinical 
biochemistry laboratories led to increased detection of hyper- 
calcaemia, and consequently to a greater demand for PTH assay in 
serum. Thus the need for more sensitive assays, which measure 
particular fragments in serum. Some of the PTH fragments are present 
in very low concentration, others are devoid of biological activity. 
Hence, the usefulness of results depends on the type of assay used for 
the measurement of PTH.
In the last decade several assays have been used in the 
measurement of PTH in serum. At present three assay types are capa­
ble of measuring PTH in serum; these are ( l)  Immunoassays (2) 
Bioassays (3) High Performance Liquid Chromatography (HPLC) .
Immunoassays
Since the introduction of RIA, PTH assays have undergone 
dramatic changes. The first RIA for PTH (Berson et al., 1963) used 
antisera raised against bovine PTH (bPTH) and ,131/  -bPTH. However, 
the assay fails to distinguish between normals and
hyperparathyroidism patients. In subsequent years, many assays 
have been developed, yet this same problem of overlap between nor­
mals and groups of patients persists. The failure of these assays and 
many others is due to the heterogeneity of PTH in circulation ( Berson 
and Yalow 1968). It is now known that there are at least four 
different forms of PTH present in circulation: intact molecule, C- ter­
minal, mid-molecule and N-terminal fragments. The demonstration
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that different forms of PTH are present in the circulation, changed 
the approach and the design of assays. Together with the availability 
of synthetic fragments, more specific assays were developed.
There are four immunoassays utilized for the measurement of 
PTH in serum. The availability of a good antibody reagent usu­
ally determines which assay to use. However, in reality each assay 
is useful in certain clinical situations. The different assays currently 
used are:
Intact molecule assay:
Antisera raised against crude PTH can be obtained with specificity 
for different regions of the amino-acid chain of PTH. Two types 
of antisera to PTH have been produced: antisera with specificity 
largely to the C-terminal fragment and antisera with specificity 
largely for intact parathyroid hormone (D’Amour et al., 1984), the 
later antisera are seemingly of two sub-populations; those
specific to the N-terminal and to the whole molecule with no
cross- reactivity to the N or C-terminals.
The new assays for the whole molecule use: (a) antisera against 
PTH (24-48) region since this is the cleavage region, (b) sequen­
tial immunoextraction of N-terminal fragments followed by mid 
region assay ( Mallette 1983 and Lindall et al., 1983) and (c)
immunometric assays, where two different antibodies raised
against two different fragments (i.e C-terminal and N-terminal) 
are utilized (Brown et al., 1987, Nussbaum et al., 1987). These 
assays were shown to be very sensitive and fast (Nussbam et al., 
1987). The use of non-isotopic labels was shown
to achieve high sensitivity assays for PTH (Brown et al.,
1987). These assays are new and await evaluation and clinical 
assessment.
C-terminal assays
Assays for the C-terminal uses antisera raised against the C- 
terminal fragment. Generally, the antisera have a high affinity for
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the C-terminal. However, it may react with the whole molecule to 
a lesser extent, but has no cross-reactivity with the N- terminal 
fragment. Although the C-terminal assays did not usually show an 
inverse relationship with serum ionized calcium, they have a good 
sensitivity and discriminates between the different groups of 
abnormal and normals patients better than other assays. This 
is presumably due to their long half life and high concentration 
in circulation. In chronic renal failure patients, C-terminal assays 
give a high value because the normal renal clearance is severely 
reduced.
The extensive use of these assays is mainly due to the scarcity of 
other good assays which measure the biologically active forms of 
the hormone.
Mid-molecule assays
The availability of synthetic fragments led to the development of 
this type of assay. Antisera are usually raised against the (43- 
68) amino-acid sequence of the hormone. Many assays able to 
detect the 44-68 fragment have been described. These assays meas­
ure the intact molecule as well as mid region fragments which did 
not contain the C-terminal sequence of PTH ( Roos et al., 1981, 
Marx et al., 1981, and Mallette et al., 1982). They have no cross­
reactivity with the N-terminal fragment, thus apparently there is 
no biological activity attached to the fragments measured by these 
assays.
N-terminal assays
Many assays are described with antisera specific to the N-terminal 
fragment (Silverman and Yelow 1973, Martin et al., 1978, Segre 
et al., 1977, Canterbury et al., 1975, Neuman et al., 1975, Segre et 
al., 1981a, Segre et al., 1981b, Morrissey et al., 1980, MacGregor et 
al., 1979 Martin et al., 1979, Martin et al., 1977, Hruska et al., 
1977, Vieira et al., 1984, Vieira et al., 1986,). These assays have a 
poor discriminating ability. The antisera are usually raised against
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crude preparation of bovine or human PTH, and they seem to 
recognize the whole molecule as well as the N-terminal fragment. 
Because the N-terminal fragment contains the amino-acid 
sequence required for biological activity, the results of the 
assays were expected to correlate with the clinical status of 
the patients. However, to date these assays have not shown a 
good correlation with primary hyperparathyroidism. The newer 
assays perform much better (Potts et al., 1983, Hawker et al., 
1984,Fischer et al., 1982), which suggests that the poor perfor­
mance of past assays might have been due to the non-specificity of 
the antisera.
On the other hand, N-terminal assays have been very helpful in 
many other situations. They have been used in chronic renal 
failure patients, where all other assays give high values because 
of renal impairment(Segre et al., 1981b, Morrissey et al., 1980, 
MacGregor et al., 1979). They have also been used in the measure­
ment of administered hPTH(l-34) (Zanelli et al., 1980). Another 
use of the N-terminal assay was in the catheterization studies for 
the localization of hyperplastic parathyroid glands ( Hruska et 
al., 1977, Martin et al., 1978, and Marx et al., 1981). The main 
reason that prevents extensive use of N-terminal assays is their 
poor sensitivity. However, with the availability of monoclonal 
antibodies together with other analytical developments moire sensi­
tive assays may be forthcoming in the near future.
High performance liquid chromatography (HPLC)
This technique has not been used routinely in the laboratory, 
however, it has the sensitivity needed to detect hPTH in serum . HPLC 
with reversed phase has been used to purify and analyse PTH (Bennet 
et al., 1981, Zanelli et al., 1981, Zanelli et al., 1983). Generally,the 
assay involves extraction of material on octadecylsilyl-silica, and the 
extracts were chromatographed using reversed phase HPLC. In most 
HPLC methods PTH in the collected fractions is assayed using radioim-
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munoassay (Zanelli et al., 1983). Three peaks were evident in the 
immuno-reactivity profile of parathyroid extract, C-terminal, N- 
terminal and intact molecule.
HPLC assay is dependent on micro-scale chemical analysis and 
biological assessment, it has not been used routinely in the 
assessment of patients samples.
Bioassays
The old generation of the different in vitro and in vivo bioas­
says are not sensitive enough to measure PTH in normal subjects 
serum. However, at present there are two bioassays which 
have sufficient sensitivity to detect PTH in serum.
a Receptor bioassay
This assay depends on the activation of adenylate cyclase in can­
ine renal cortical membranes (Abbott et al., 1980, Nissenson et 
al., 1981). This in vitro bioassay measures both intact and bio­
logically active hPTH(l-34) (Abbott et al., 1980) and the sensi­
tivity can be enhanced by the addition of the analog of 
guanosine-triphosphate, 5’-guanylimidodiphosphate. The detection 
limit of the original assay was too high to detect PTH in normal 
serum, it has subsequently been reported that the assay could be 
applied to measure PTH in normal serum (Avioli et al., 1981). 
The use of human instead of canine membranes giving the same 
sensitivity has also been reported (Niepel et al., 1981)
b Cytochemical Bioassay
This assay depends on the stimulation of glucose-6-phosphate 
dehydrogenase activity in the distal convoluted tubules of 
guinea-pig kidney maintained in vitro ( Chambers et al., 1978). It 
has been developed using techniques used in the ACTH cyto­
chemical bioassay (Chayen et al., 1972). The enzyme activity is 
measured by microdensitometry ( Chambers et al., 1978). This 
technique has been used by different groups for the measurement of 
PTH (Chambers et al., 1978, Fenton et al., 1978, Goltzman et
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al., 1980) and a modification of the original technique has also 
been reported (Posillico et al., 1981). Human and bovine synthetic 
biologically active fragments gave a parallel response (Goltzman et 
al., 1980) and equimolar to that for intact bovine hormone. It was 
estimated that biologically active hormone present in the circula­
tion of normal individuals ranged between 1-30 ng/L (1-30 pg/ml) 
(Goltzman et al., 1980, Fenton et al., 1978, Chambers et al.,
1978) as biologically active PTH in serum was reported to con­
stitute only 10% of that measured by RIA (Allgrove et al., 1983).
The assay is capable of distinguishing between hypo-, hyper­
parathyroid patients and normal patients (Goltzman et al., 
1980, Fenton et al., 1978, Allgrove et al., 1983). Despite the 
high sensitivity of this assay, it is not expected to be used rou­
tinely in the laboratory, because it is not practical and is 
cumbersome, It could, however, serve as a reference method for 
comparing the different assays, and provide another means of 
confirming the diagnosis in the difficult cases.
The methods mentioned above are theoretically divided into two 
groups; those which measure the biologically active forms of PTH, 
which are expected to correlate with the clinical situation of the 
patients, and those which measure the fragments which display no 
biological activity but are present in high concentration in the 
plasma, and have 10 to 15 times longer half-life than the biologically 
active fragments. It has been easy to measure the inactive fragments, 
because of their high concentration and longer half-life. On the other 
hand, measurement of biologically active fragments presents a 
problem, because they demand a very highly specific and sensitive 
assay. Despite the common use of assays which measure biologically 
inactive fragments, the assay of biologically active fragments is 
needed for the understanding of the physiology of PTH. Biologically 
inactive fragments give no information about the physiology and the 
minute to minute change in the secretion of the hormone. Their assay 
correlates with glomerular filtration rate, on which their clearance
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depends.
For the measurement of PTH in body fluids, immunoassays are 
preferable because they are fast, easy and can handle a large number 
of samples. The main disadvantages of many of these procedures avail­
able currently in that fragments devoid of biological activity are 
measured. Hence, there is a need for improved immunoassays that will 
apply to biologically active fragments of PTH.
The antibody plays the major role in the characteristics of 
immunoassays. The sensitivity and specificity of the assay is usually 
determined by the antibody, hence, assays which use polyclonal 
antibody tend to suffer from a high cross-reactivity and modest 
sensitivity.The introduction of monoclonal antibodies is expected to 
yield more specific and sensitive assays for the different fragments of 
PTH.
1.3. AIMS OF THE PRESENT WORK
The measurement of parathyroid hormone plays a key role in the 
differential diagnosis of hypercalcaemia. The procedure for the assess­
ment of parathyroid status has improved over the years, thus also con­
tributing to the understanding of the etiology of hypercalcaemia. Dur­
ing the past decade many assays have been developed which measure 
one form or another of PTH in serum. However, the methodologies, 
tend to be diverse and unlike other peptide hormones, the antibodies are 
rather limited from the viewpoint of quality and assay availability. A 
better assay could be developed, standardized, and put into a wider use. 
In particular, application of such assay to the biologically active frag­
ment of PTH might also assist in the laboratory investigation of PTH- 
related diseases.
We therefor undertook the raising of polyclonal and monoclonal 
antibodies to the hPTH(l-34). In the early stages, polyclonal antibodies 
were raised in the goat and with that material various detection sys­
tems for the antibody were devised and the assay procedure developed. 
A maior part of the project was dedicated to the development of
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monoclonal antibody to hPTH(l-34). Attempts were made to identify 
the most effective immunization schedule and animal species combina­
tion for cell fusion. The latter included mouse-mouse, rat-rat and rat- 
mouse systems, and was further expanded to goat-mouse and goat- 
heteromyeloma (ovine-murine hybridoma) fusions.
The antibodies produced as a result of this work were applied to
the detection of PTH-like molecules in tissues and to the construction
wjthof an immunoassay for use'body fluids.
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CHAPTER 2
DEVELOPMENT OF SCREENING ASSAYS 
FOR MONOCLONAL ANTIBODIES
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2.1. INTRODUCTION
The success or failure of the production of a monoclonal anti­
body is largely governed by the screening procedures employed. The 
concentration of monoclonal antibody that can be produced is 
theoretically very small, especially in the early stages,where only a 
few cells of those growing produce the desired antibody.
A good screening assay should not just be able to detect an 
antibody, it must be rapid, sensitive, reliable, and recognize all anti­
bodies of all types of immunoglobulins. Such a system is an essential 
pre-requisite during the screening stages for the detection of hybrid 
cell lines secreting the required antibody. The detection and selection 
of each antibody is limited by the assay, and it is important that, the 
assay chosen for this purpose has the following features.
Sensitivity
The assay must be very sensitive to allow the detection of a 
small concentration of antibody secreted by the hybrids in the 
very early stages. It is one of the steps which severely limit the 
possible selection of antibody.
Specificity
It is desirable to select only those cells which produce an anti­
body specific to the antigen. The assay chosen has to be accordingly 
capable of meeting this requirement. It may not however,be possi­
ble to select for an absolute specificity from the beginning.
Simplicity
The simplicity of the assay as well as the efficiency to handle 
a large number of samples are the other requirements for screening 
systems. It is necessary to detect and select the desired clone very 
early. Time is very important, especially when large number of 
clones per well are expected. The hybrids exert a very diverse 
growth characteristics, some very important hybrids may be lost in 
the detection and selection step, and careful selection of a rapid, 
simple assay will minimize the loss.
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Reliability
The whole feature of the screening assay depends on the relia­
bility and accuracy of the assay. The detection rate of the assay 
must be consistent, and must be accurate to avoid the waste of 
valuable time pursuing false positive cultures, or most important 
the loss of very valuable positive cultures.
It is appropriate to say that, the assay must be chosen with 
regard to the nature of antigen and the uses for which the antibodies 
are intended(Edwards 1981, Galfre and Milstein 1981, Catty et al., 
1981, Foster 1982).
In the last decade many assays have been used to detect 
monoclonal antibodies, some of which are described in the study of 
antibody formation at the single cell level (Cunningham 1973). Others 
were those used with the polyclonal antibody adapted for the detec­
tion of monoclonal antibodies. Generally it is possible that many 
immunological assays can be adapted for the detection of monoclonal 
antibody within the limits of screening assays.
A brief account of the most commonly used assays for screening 
hybridoma supernatants is given below, with more attention paid to 
those used in the screening of antibodies to soluble antigen.
Binding assays are the most popular, and commonly used 
assays in hybridoma screening, because of their simplicity and ability 
to detect all types of immunoglobulins. These are particularly useful 
for the detection of monoclonal antibodies against soluble antigens.
Radioimmunoassay (RIA)
Since the introduction of RIA (YaJow and Berson 1960) various 
modifications have been used for screening monoclonal antibodies (Soos 
and Siddle 1982,and Baxter et al., 1982).
These have also been adapted for the same purpose, to microtitre 
plate in conjunction with solid phase immunoassay (Goding 1986, 
Catty et al., 1981, Galfre and Milstein 1981, and Hudson and Hay
1980). In this type of assay, the antigen is adsorbed on to a solid
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phase support. The antibody solution is added to the solid phase 
antigen followed by the labelled antiglobulin. This type of assay 
eliminates the separation step of the classical RIA, and this is 
accomplished by washing the plate. The labelled antiglobulin serves 
as a general reagent, detecting all types of immunoglobulins.
Enzyme linked immunosorbent assay (ELISA)
ELISA was first described in the early seventies (Van Weeman 
and Schunrs 1971, Engval et al., 1971),since then, the ELISA assay has 
expanded and the application have been covered in several publications 
( Bidwell et al., 1976, Voller et al., 1976 ,1979 and 1981, Voller and 
Bidwell 1980).
The use of ELISA in the detection of monoclonal antibody was 
demonstrated (Kennett 1981, Sundar Raj et al., 1982, and Douillard et 
al., 1980). Enzyme labelled and radiolabelled protein A was used as a 
general reagent (Suter 1980, and Nowinski et al., 1981). The ELISA 
makes use of the microtiter plate involving the same steps as those 
described above in the microtiter plate solid phase RIA, except that 
the radiolabel is substituted by enzyme labelled antibody. After 
separation of bound from free antibody by washing, a colourless 
substrate is added, and a soluble, coloured product is formed. The 
optical density of the solution is then measured in a spec­
trophotometer.
Immunofluorescence assay (IFA)
Those are a group of assays which use a fluorescence-labelled 
antibody instead of enzyme or radio- labels. Fluorescein-labelled anti­
body was first described by Coons et al (1941), since then a whole 
range of assays based on fluorescein- labelled antibody has been 
reported (Johnson et al., 1979 and London and Kamel 1981). 
Fluorescein-labelled antibody has been employed in the simultaneous 
screening and cloning of hybridomas using fluorescein-activated 
cell sorter (FACS) (Park et al., 1979, Dangl and Herzenberg 1982). 
These labels are commonly used in the identification of monoclonal
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antibodies directed against cellular antigens (Epstein 1981).
Biological assays
These assays are based on the effect of monoclonal antibody on 
the biological activity of the antigen. They are not very popular 
in hybridoma screening as they are cumbersome and cannot fulfill 
the requirements for a screening assay. The main features of the assay 
are that (i) the antigen does not have to be purified for the assay ,and 
(ii) the inhibitory effect gives some information about the antibody 
binding site on the biologically active molecule.
Haemagglutination assays
This type of assay, first described by Coombs (1981), was 
adapted for hybridoma screening (Galfre and Milstein 1981, Catty 
et al., 1981). They are qualitative assays, where the antigen is chemi­
cally attached to the surface of red blood cells. In the presence of anti­
body haemagglutination occurs. They are usually less sensitive than 
the binding assays, fail to detect some clones, and require a large 
amount of antigen. Direct and indirect haemagglutination assays can be 
used (Fraster et al., 1982)
Immunocytochemical assay: This assay is not considered suitable for 
screening assays of hybridomas, because it is very tedious and time 
consuming. However,if the antibody is finally going to be used in 
immunocytochemistry, this assay could be used in conjunction with 
other primary assays, where those found positive could be subjected to 
this assay when the time is not critical in selection.
The assay uses tissue which has been fixed and treated with 
different solutions. This sometimes dramatically changes the 
antigen, which may leads to different results ( Milstein et al., 1983)
Having considered the various posibilites of suitable screening 
system, available reagents and the cost of assays. In this chapter, the 
development of indirect ELISA for the detection of monoclonal anti­
body to hPTH(l-34), and the optimization of liquid phase RIA ( 
Zanelli et al., 1980) are presented. The outline of direct and indirect
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ELISA systems are shown in figure 2.1.
2.2. RADIOIMMUNOASSAY (RIA)
2.2.1. Chemicals and reagents
hPTH(l-34) and bovine serum albumin(BSA) RIA, grade, 
were supplied by Sigma chemicals Ltd. Sodium iodide was sup­
plied by Amersham chemicals Ltd. All other reagents were of analyt­
ical grade from BDH chemicals Ltd.
2.2.2. Iodination of hPTH(l-34)
The incorporation of iodine 125 into proteins has been used for 
labelling antigens since the early days of radioimmunoassay. The 
iodine is substituted onto the aromatic side- chain of tyrosine resi­
dues yielding a stable compound. It is also possible to substitute onto 
phenylalanine and histidine residues , although the substitution is 30 - 
80 % times less than that for tyrosine.
The incorporation of iodine into hPTH(l-34) was found to be 
difficult and accompanied by other problems, not least the loss of 
activity.
Chloramine T method is the most common procedure used for 
the iodination of proteins. Other methods offer some advantages but 
the chloramine T method, for its simplicity and short time needed to 
accomplish the labelling is favourable. hPTH(l-34) has been iodinated 
by various other methods, but these showed no advantage over the 
chloramine T method. The only method which has not been used for 
the iodination of PTH, so far, is the Iodogen method.
In this study chloramine T method as well as the iodogen method 
were used to iodinate hPTH(l-34).
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Antigen adsorbed on the plate wells by 
addition of the antigen in coating buffer 
to the wells and incubatation.
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Addition of sample containing the anti­
body to the antigen coated wells, the 
antibody should bind the solid phase 
antigen.
1
Addition of enzyme labelled anti-species 
antibody to bind the first antibody.
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Figure 2.1 a: Representation of the steps involved in indirect 
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Antibody to the desired antigen is 
adsorbed on the wells of ELISA plate by 
adding the antibody diluted in coating 
buffer to the wells and the wells incu­
bated.
The free sites blocked with gelatin or 
other protein, and the sample containing 
the antigen is added and incubation is 
continued. The antigen should bind the 
solid phase antibody.
After washing the wells, antibody binds 
different determinant of the antigen and 
labelled by an enzyme is added to the 
wells and incubated.
o 0 •o a o 
■ ♦ £ • ^  °
A # -
Substrate is added to the wells, and a 
colour product is formed, which can be 
measured spectrophotometrically.
Figure 2.1 b: Representation of the steps involved in double 
antibody sandwich ELISA for measuring antigen (adapted 
from Voller et al., 1979).
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Chloramine T method : The method used was that of Zanelli ( 
Zanelli et al., 1980). Briefly, hPTH(l-34) was dissolved in 0.1 M acetic 
acid to the concentration of 100 ug/ml. Aliquots (20ul-2ug) were snap 
frozen and stored at -70°C until needed for use. The stored material 
was used over two years.
Antigen (2ug) brought to room temperature and 100 ul of phos­
phate buffer 0.2 M was added to it. The contents of the tube were 
mixed and 1.5 or 0.5 mCi of sodium iodine was added. Chloramine T 
(20ul,2.66mg) was added to the tube, mixed for 20 seconds and the 
reaction stopped by the addition of 50 ul of 3.6 mg/ml sodium meta­
bisulphate. The tube mixed and 1 ml of phosphate buffer 0.02 M 
containing 0.5% BSA was added followed by 20 ul of 2 mg/ml potas­
sium iodide. The mixture was then subjected to purification. The 
purification was done either with sephadex G15 or Quiso . Early 
purification was done using QUISO, later work was done on sephadex 
G15. The iodinated hormone was eluted with phosphate buffer 0.02 
M pH 7.4 containing 0.5% BSA. The fractions containing the iodi­
nated hormone eluted first and those which give high counts were 
further assayed for immunoreactivity. The best fraction was ali- 
quoted in 50 - 100 ul aliquots and stored at —40°C .
Iodogen method : The method used was similar to that of Hampten 
( Hampten 1982). Iodogen was dried on the inner walls of 
polyethylene tubes as described by Salcinski (Salcinski et al., 1979).
1,3,4,6 Tetrachloro 3 6 diphenylglyco uril was dissolved in analar 
dichloromethane to the concentration of 1 mg/ ml and 20 ug were 
adsorbed to the walls of polypropylene tubes.
To a tube containing 20 ug of iodogen, 0.5 mci sodium iodide was 
added followed by 2 ug of hPTH(l-34). The tube mixed occasionally 
for 10 minutes. Then 20 ul of 1 mg/ ml sodium metabisulphate 
was added followed by 1 ml of phosphate buffer pH 7.4 containing 0.5 
% BSA. Potassium iodide (20ul, 2mg/ml)was then added, and then the 
mixture was transferred onto a G15 sephadex column. The labelled-
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peptide was eluted using phosphate buffer pH 7.4 containing 0.5 % 
BSA. Fractions of approximately 1 ml were collected. The fractions 
were counted, and those with high counts were tested for immunoreac- 
tivity.
2.2.3. Method 
Buffers
Barbitone buffer pH 8 .6  was made as follows: 10.39 g of sodium 
barbital,3.722 g of ethylenediamine tetra-acetic acid sodium salt 
(EDTA), 0.1 mg thiomersal were made up to one liter with distilled 
water. The pH adjusted to 8 .6  using 0.1 N HC1. The buffer kept at 4°C 
for not more than four weeks.
Working buffer
0.5 % BSA and 0.1 % Tween 20 were added to the barbital 
buffer before use. This buffer was kept at 4°C for not more than two 
weeks. Labelled antigen and antibodies were diluted in the same 
buffer.
Procedure
To duplicate LP3 tubes 200 ul of working buffer was added, fol­
lowed by 100 ul of sample or control. The tubes were shaken, and 
100 ul of labelled hPTH( 1-34) was added to each. The contents were 
mixed and incubated at 4°C overnight. Next day, 100 ul of pre­
cipitating antibody was added to all tubes except totals, the tubes 
mixed and incubated at 4°C for 2.5 hours. Polyethylene glycol 6000 
(200ul, 12% w /v) was added to all tubes except totals, the tubes were 
mixed and incubated at 4°C for 1/2 hour. The tubes were centrifuged at 
4°C in Beckman J 6 refrigerated centrifuge for 45 minutes at 3000 
rprrr. The supernatant was aspirated and the pellet counted for 100 
seconds in LKB multigamma counter.
2.3. ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
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2.3.1. Chemicals and reagents
Donkey anti-mouse serum, donkey anti-mouse horseradish peroxi­
dase labelled (D x M HRPOase), affinity purified donkey anti-mouse 
IgG, donkey anti-goat horseradish peroxidase labelled (D x G 
HRPOase),were all supplied by Guildhay Antisera Ltd. Mouse IgG 
was supplied by Sigma Diagnostics Ltd. Polyvinyl chloride (PVC) 
and polystyrene plates were supplied by Dynatech. Sheep anti-rat 
horseradish peroxidase (S x R HRPOase) was supplied by Serotec Ltd.
2.3.2. Method 
Buffer
Coating buffer
Carbonate/bicarbonate buffer,0.1M, pH 9.6,was prepared by dis­
solving 1.59 g of Na2C 03 and 2.93 g of NaHC03 in one litre distilled 
water and the pH was adjusted to 9.6. The buffer was stored at 4°C 
for up to four weeks.
Washing diluent buffer
0.15 M phosphate buffered saline pH 7.4; 8 g of NaCl, 0.2 KC1. 
1.15 g of N a2H P04 and 0.2 g of KH2P 04 were dissolved in one litre of 
distilled water. The pH was adjusted to 7.4. Usually, this buffer is 
prepared 10 X concentrated, and the working buffer diluted when 
needed. Gelatin (0.1%) and Tween 20 (0.05%) were added before use, 
and the buffer used within two days.
Substrate buffer
Phosphate citrate buffer pH 5.3; 4.666g of citric acid,7.298g of 
Na 2HPO 4 were dissolved in a litre of distilled water. The pH was 
adjusted to 5.3. Generally, 500 ml was prepared each time and kept at 
4°C for not more than four weeks.
Substrate solution
To 100 ml of substrate buffer 40 mg of ortho phenylenediamine 
(OPD) was added, mixed and 40 ul of H 202 (30 % v/v) was added to
it. The solution was prepared just before use, and usually not more
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than 1 hour. The solution was always made up in a dark bottle as the 
substrate was light sensitive.
Procedure A
1: A PVC plate was coated with antigen diluted in coating buffer, to
the concentration of 2 ug /  ml. The plate incubated at 4°C over­
night or 2 hours at 37° C .
2: The plate washed once with PBS, and blocked with the addition of
200 ul of PBS-1 % BSA or 0.1 % gelatin for 1 hour at 37° C .
3: The plate washed again with PBS, and the samples or controls were
added to it and incubated at 4°C overnight or for 2 hours at 37° C .
4: The plate washed 6-9 times with washing buffer, shaken a few
times to remove any fluid, and 200 ul of HRPOase labelled anti­
body diluted in washing buffer was added to all wells. The plate 
incubated at 37° C for 2 hours.
5: The plates were washed 6-9 times with washing buffer, shaken
dry and 150 ul of substrate solution was added to all wells. The
plates were then incubated for 30 minutes at 37° C .
6: The reaction was stopped by the addition of 50 ul of 2.5 M H 2S 04,
and the plates read at 490 nm in an Automatic ELISA Plate Reader.
The outer wells were not used as they might have given greater 
variability in absorbance (Kirka et al., 1980). The format was shown 
in figure 2.2 a.
Procedure B
The procedure was basically the same as in procedure A with 
the format being somewhat different. Each sample and control was 
added to two different wells, one containing antigen, the other 
without antigen ( used as blank), the positive result then is the 
difference in
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Figure 2.2(a): The format for ELISA method A. Column 12 
was used for HRPOase-labelled second antibody only, 
andcolumn 1 was used for substrate only.
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Figure 2.2(b): The format for ELISA method B. Rows A,C,E 
and H were used as blancks. Column 12 and 1 were used 
for HRPOase labelled second antibody and substrate respec­
tively.
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absorbance between the the antigen well and the blank ( non antigen 
well). This measure has been taken to avoid false positive results, as 
some immunoglobulins stick to plastic very strongly even in the 
presence of high concentration of other proteins, or the blocking with 
high concentration of other irrelevant proteins. The format of the 
assay is shown in figure 2.2 b.
2.3.3. Testing of solid phase
Using ELISA procedure A, different solid phase supports were 
assessed for their suitability for use in the indirect ELISA system.
Mainly two different types of solid phases were employed , polys­
tyrene and polyvinyl chloride plates. Polystyrene and polyvinyl 
chloride plates were supplied by Dynatech and other polystyrene plates 
by Alpha .
Using ELISA procedure A and positive polyclonal serum, the plates 
were tested for their efficiency in adsorbing the antigen. The antigen 
was diluted to the concentration of 2 ug /ml. The plate were coated 
with 200 ul per well of antigen overnight at 4°C . The positive 
antiserum was serially diluted, and applied to the plate. The plates 
were incubated for 2 hours at 37° C and developed as mentioned in 
procedure A.
2.3.4. Glutaraldehyde sensitization
The glutaraldehyde sensitization method (Stafford and Kilgallan 
1980) was used to enhance the efficiency of adsorption. Glu­
taraldehyde solution, 200ul(l%) was added to polystyrene plate wells 
and incubated for 3 hours at 37° C . The plate was washed extensively 
with PBS and used in indirect ELISA method as mentioned above.
2.3.5. Testing the effect of different coating buffers
Although originally the coating buffer used was 
carbonate/bicarbonate buffer, a various ELISA methods use different 
buffers mainly because they enhance the adsorption more effectively 
than the carbonate/bicarbonate buffer. For hPTH(l-34) using
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radiolabelled hormone the optimum pH was found to be 7.4 (Nussbam 
et al., 1981). The buffers tested were carbonate/bicarbonate buffer pH
9.6 and phosphate buffered saline pH 7.4. PVC plate was coated with 
antigen diluted in each buffer, and a positive polyclonal serum was used 
to assess the amount of antigen adsorbed to each plate, exactly as men­
tioned above for the testing of solid phase support.
2.3.6. Testing different blocking agents
The two standard blocking agents BSA and gelatin were tested for 
their efficiency in reducing the non specific binding. BSA and gelatin 
were supplied by Sigma chemicals and the concentration ranged 
between 1-2 %. They were dissolved in PBS and applied to the plate. 
The plates were incubated for 1 hour at 37°c .
2.3.7. Testing the effect of detergent on antigen antibody binding
The hPTH(l-34) polyclonal antiserum was diluted in washing 
buffer containing detergent Tween 20, and diluted in PBS without 
the detergent Tween 20. It was then applied to PVC plates coated with 
antigen. The plates were developed as mentioned above in procedure 
A.
2.4. RESULTS
2.4.1. RIA
2.4.1.1. Iodination
The iodination of hPTH(l-34) with Chloramine T method was 
very simple. It takes only one hour and a half to accomplish. 
Purification of the labelled hormone using Quiso or sephadex G15 
was very easy, and reproducible, even on small column of 5 cm long as 
shown in figure 2.3a and 3.2b.
The reproducibility of the method, however, was very poor, 
despite the use of high concentration of sodium iodide, up to 1.5 mCi. 
Because of the constraints of the University safety regulation, and a 
lower levels of radioiodinating had to be used in the routine procedure.
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Figure 2.3(a): Sephadex G15 elution profile of radiolabelled 
hPTH(l-34) prepared by chloramine T method. Column 
lenght= 5 cm, volume in each tube= 1ml.
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Figure 2.3(b): Sephadex G15 elution profile of radiolabelled 
hPTH(l-34) prepared by chloramine T method. Column 
lenght=25 cm, volume in each tube= 1ml.
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The effect of using high concentration of sodium iodide on the iodina­
tion was shown in figure 2.4. It appears that 0.5 mCi can produce agood 
labelled, and sufficient for iodination. From those results the use of 0.5 
mCi was adapted, and used throughout the period of this project.
From six iodinations using Chloramine T method and 0.5 mCi of 
radioactivity each time, only one produced labelled product of high 
specific activity which gave a maximum binding higher than 50%. 
However, because of the lack of its reproducibility the method was 
abandoned in favour of other mild methods.
It appears that, Iodogen method has not been used in the iodina­
tion of PTH. It is a more gentle method, the oxidation is very mild 
and causes little damage to the hormone. It was first described by Sci- 
lacinsk (Scilacinsk et al.,1979). When used here for hPTH(l-34) for 
example, the radiolabelled hPTH(l-34) produced in four separate 
runs, each gave 85-95% binding under comparable assay conditions. 
This method was found to be very consistent. The elution profile of 
the labelled hormone from sephadex G15 is shown in figure 2.5. 
The immunoreactivity of the different fractions assayed using 
antiserum to hPTH(l-34) was shown in figure 2.6.
2.4.1.2. Optimization
The assay have been adapted for polyclonal antibody measure­
ment. The dilution of second antibody and the normal serum were 
titrated to give the best combination for antigen-antibody complex 
precipitation. The optimized assay, was then compared with the 
precipitation of the complex using dextran coated charcoal. Donkey 
anti-goat serum was diluted 10,20,30 and 40 times, each dilution was 
tested for precipitating the labelled hPTH(l-34) and goat ati-PTH(l- 
34)anti-serum complex. The results obtained are shown in figure 2.7. 
Normal goat serum was added to give initially 1 in 10 dilution of don­
key anti-goat serum and subsequently final dilution of 1:100, 1:200, 
1:500, 1:1000. The precipitation of the complex with 0, 1:500 and 
1:1000 normal goat serum dilutions was almost twice as that with
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2.5: Sephadex G15 elution profile of iodinated 
hPTH(l-34) prepared by iodogen method. Column lenght= 
5 cm, volume in each tube= 1ml.
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1:100 and 1:200 as can be seen in figure 2.8. The use of second anti­
body was compared with 5% dextan coated charcoal, where 100 ul 
of charcoal was added to each tube and incubated for 10 minutes. 
As shown in figure 2.9, although the percentage binding of dextran 
coated charcoal was higher , the NSB was very high 22%. The second 
antibody and PEG method give NSB of less than 2% .
The same procedure was used to titrate the second antibody and 
the normal serum for the rat antibody.
2.4.2. ELISA
The ELISA method A was used in the early work. The blank 
value was found to be more useful as a negative control, and has been 
used in all later work.
2.4.2.1. Solid phase support
The two different solid phases available were tested for their 
adsorption of hPTH(l-34). It is evident from figure 2.10 that 
polyvinyl chloride (PVC) plates adsorb hPTH(l-34) better than 
polystyrene plates. Glutaraldehyde sensitization of polystyrene plates 
increased the adsorption of antigen to the sensitized plates over the 
non-sensitized but less than that adsorbed by the PVC plates. From 
the results in figure 2.10, it was decided to adapt PVC plates for 
use in antibody screening. The results of chequerboard ELISA for the 
goat serum using PVC plates were shown in Figure 2.11.
2.4.2«2. Blocking agent
The two most commonly used blocking agents were tested. The 
results in figure 2.12 show that there is no difference between BSA 
and gelatin in reducing the non-specific binding. Casein was found to 
block all the activity if used as blocking agent or used in the washing 
and dilution buffer.
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2.4.2.3. Effect of Tween 20 on Antigen Antibody binding
When the goat polyclonal anti-serum was diluted in PBS with 
and without Tween 20, no difference could be seen between these 
two ways of diluting serum in the standard ELISA B method. When 
the same was applied to rat positive serum, the results were clearly 
different. Figure 2.13 shows the results obtained with the rat serum.
2.5. DISCUSSION
2.5.1. RIA
The liquid phase RIA adopted in this study is very sensitive for 
the measurement of antibodies to hPTH(l-34), it detected antibody in 
serum diluted many times . It is expected that the method will be 
sensitive enough to detect monoclonal antibody in tissue culture super­
natant.
The liquid phase RIA has different characteristics from solid 
phase RIA. The liquid phase assay has been shown to have advantages 
over the solid phase. Moreover, the solid phase ELISA developed util­
ize the same principle with the many advantages of using an enzyme 
label instead of radiolabel. As mentioned before, the use of both sys­
tems in the screening for hybridoma secreting antibody is a precaution 
step in case of the failure of either system, as well as the expectation 
that monoclonal antibody specificity will allow each system to detect 
antibodies different from each other.
2.5.2. ELISA
The many advantages ELISA has over the RIA explains the exten­
sive use of it in the detection of antibody and especially in screening 
for monoclonal antibody over the past decade.
The ELISA developed in this study has been shown to exhibit the 
characteristics required for the screening of hybridoma products.
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The assay was first set up with polyclonal antiserum, but is expected 
also to be applicable to monoclonal antibodies, may be with some 
minor modifications. The solid phase has been optimized, and the PVC 
plates were found very suitable. The sensitized polystyrene could also 
be used, although the NSB was found to be higher than that for PVC 
plates. The optimum concentration of hPTH(l-34) was in the range of 
lug/m l for the polyclonal antibody. However, because of the 
affinity of monoclonal antibody and the concentration in the super­
natants 2ug/ml is adapted for screening hybridoma products.
The assay as it stands at this stage, is cheap, fast, capable of han­
dling a large number of samples, and is easy to perform. The uses of it 
as well as some of the modifications and problems encountered will be 
discussed in the relevant sections of this work.
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CHAPTER 3
MOUSE AND RAT MONOCLONAL ANTIBODY
TO hPTH(l-34)
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3.1. INTRODUCTION
The univalent antibody is the product of a committed spleen cell 
fused with an immortal myeloma cell. The fusion of B-lymphocyte 
from any species with myeloma cell line from another species is 
theoretically possible. However, the stability of the resultant 
hybridoma cells, and their secretion characteristics would be governed 
by many factors which are not clearly understood at present.
To date only mouse and rat myeloma cell lines are available. 
The mouse myeloma cell lines originate from Balb/c mice and the 
rat myeloma cell lines from Lou/c rats. The in vivo production of 
monoclonal antibody requires the use of compatible species, and that 
restricts the choice of animals which can be used for the produc­
tion of monoclonal antibody. The cross-species fusion is possible, but 
the success has so far been limited to certain species. Of these the rat- 
mouse combination is probably the most important.
Historically the mouse system was the first to be used in the 
production of monoclonal antibody to pre-determined specificity( 
Kohler and Milstein 1975). Since then the technology expanded 
and the methodology has been refined. The mouse system has 
been used extensively as it has some advantages over the rat system. 
The mice are easier to handle, they are generally good responders,and 
there are several cell lines available; these cell lines have been well- 
studied and the fusion methodology optimized.
The success of the mouse system can be demonstrated by the 
wealth of literature and the commercial products available on the 
market.
Rat cell lines on the other hand, should be theoretically better 
than the mice cell lines. Because of their large size, the rats give twice 
the spleen cell number of mice, they are easier to bleed and more 
blood is obtainable. They also produce more ascites than mice (about 
5-10 times more than mice). The cell lines, in particular, grow slower 
than the mice cell lines, hence, do not necessitate early cloning. The size
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of the cell lines is smaller than that of mice; this allows the use of 
ratios near 1:1 spleen to myeloma,and this is expected to increase the 
number of positive clones.
Despite the apparent advantages the rat system have over the 
mouse system, the use of rat in monoclonal antibody work appears to 
have been surprisingly limited. A literature survey shows there are 
not many reports of rat-rat fusions, although it was claimed that 
rat-rat fusion has a greater stability (Clark et al., 1983) and have the 
same efficiency as the mouse system.
3.2. MATERIALS AND METHODS
3.2.1. Reagents and chemicals
hPTH(l-34),BSA-RIA grade,Carbodimide,were all supplied by 
Sigma. Rat typing sera. Rat monoclonal typing Kit, and mouse typing 
sera were from Serotec Ltd, agarose grade A, and saphacel anion 
exchange resin from Pharmacia chemicals.
3.2.2. Cell culture media
Media used were RPMI and DMEM both supplied from Gibco. 
Fetal calf serum (FCS), penicillin/streptomycin, L-glutamate, 
sodium pyruvate, Hypoxanthine Aminopterin Thymidine (HAT) all 
purchesed from Gibco.
Tissue culture plates ( 96, 24, 6 well/plate) and Flasks ( 25 and 75 
ml flasks) were purchased from Falcon, Costar or Gibco.
Preparation of media
Standard culture media and its concentrated form (X10) were sup­
plied without L-glutamate; L- glutamine was added to it prior to use. 
The media was diluted with sterile distilled water as required. The pH 
of the media was adjusted after the addition of sodium carbonate with 
sodium hydroxide to bring the pH near neutrality. The media used 
throughout was either serum-free containing sodium bicarbonate and 
neutral in pH or another media with 10% FCS ( fo r  example RPMI 10%
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FCS). The later media also contained sodium pyruvate, L-glutamine 
and penicillin/streptomycin. The selective media was that with 10% 
FCS and HAT added to it.
3.2.3. Preparation of thym ocyte conditioned media
Thymus glands from 4-5 week old mice were used. The mouse 
was rinsed in ethanol, the thymus glands removed and were washed in 
serum free media(RPMI). The thymus glands were then pressed 
through 50 mm mesh stainless steel screen into a 10 cm petri dish 
containing 5ml serum free RPMI. The capsule was discarded and the 
clumps of cells dispersed using a pasteur pipette. Then the cells were 
washed twice in serum-free RPMI. The cells were counted and 
resuspended in RPMI containing 20% fetal calf serum, at a density of 
5x 106 cells/ml. The cells were cultured for four days at 37°C in 
humidified atmosphere of 5%C02 • The cell debris were removed by 
centrifugation and the supernatant aliquoted in 10 ml tubes and 
kept frozen at — 70° C until used. Four to five mice were processed at a 
time.
3.2.4. Conjugation of hPTH(l-34)
hPTH(l-34) were conjugated to BSA using the carbodimide 
method. hPTH(l-34),173ug was dissolved in 3ml of dimethyl sul- 
phoxide. Solutions of BSA(881ug) and carbodimide(585ug) were made 
in 3ml and 4 ml of distilled water respectively. The BSA solution was 
mixed with the hPTH solution for a few minutes, then the carbodi­
mide solution was added to them. The components were mixed and 
then left stirring on a magnetic stirrer at a low speed overnight. Then 
the solution kept at 4°c for another 24hours before it was freeze dried.
3.3. IMMUNIZATION
3.3.1. Mice immunization:
Mice, 8-10 weeks old (supplied by the Animal Unit University of 
Surrey) were divided into four groups for immunization. hPTH(l-34)
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in the free form or conjugated to BSA as mentioned above was used 
as immunogen.
The mice were immunized with the immunogen through one of 
three routes, intra-peritoneally (i.p), intra-muscularly (i.m) in three 
sites in the back legs, or intra-dermally (i.d) in different sites along 
the back. The immunogen was mixed 1:1 in complete Freunds adju­
vant in the first injection, then with the immunogen dissolved in 
sterile distilled water in the other two boosts. The mice were left to 
rest for three to four weeks between immunization and for the same 
period before they were boosted for fusion. Full details of the 
immunization schedule and materials used are shown in table 3.1.
3.3.2. Rat immunization:
Lou/c rats, 6-8 weeks old ( supplied by the Animal Unit 
University of Surrey) were divided into three groups for immunization. 
The rats were immunized with hPTH(l-34) in the free form mixed 
1:1 with complete Freunds adjuvant in the first immunization, then 
twice with the hPTH(l-34) in the free form dissolved in sterile dis­
tilled water . The rats were left for four weeks between immunization 
and for the same length of time before they were boosted for fusion.
The rats were given 0.5 ml of the immunization mixture through 
one of three routes, intra-peritoneally(i.p), intra-dermally (i.d) in 
different spots or intra-muscularly (i.m) in both back legs. The 
detailed schedule and materials used for immunization are given in 
table 3.2.
3.3.3. Secondary in-vitro immunization
After primary immunization of the mouse, spleen was removed 
aseptically into 5ml of serum-free RPMI. The spleen was pressed 
through a 50mm mesh and the clumps of cells were dispersed by using 
a pasteur pipette. The cells were left standing for 5 minutes to allow 
the clumps
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Table 3.1
Mouse immunization schedule
Group One
Immunization No.of animals Immunogen ug/mice Adjuvant ratio BCG ul Route of immunization
1 6 10 ug free 1:1 50 i.p
2 6 5 ug free - - i.p
3 6 5 ug free - - i.p
Group Two
1 6 10 ug free 1:1 50 i.d
2 6 5 ug free - - i.d
3 6 5 ug free - - i.d
Group Three
1 6 10 ug free 1:1 50 i.m
2 6 5 ug free - - i.m
2 6 5 ug free - - i.m
Group Four
1 13 13.5 ug conjugated to BSA 1:1 50 i.p
2 13 5.3 ug free - - i.p
3 12 5 ug free - - i.p
i.p: Intra-peritoneal 
i.m: Intra-muscular 
i.d: Intra-dermal
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Table 3.2
Rat immunization schedule
Group One
Immunization No. of animals Immunogen ug/rat Adjuvant ratio BCG ul Route of immunization
1 2 10 ug free 1:1 50 i.p
2 2 5 ug free - - i.p
3 2 5 ug free - - i.p
Group Two
1 2 10 ug free 1:1 50 i.d
2 2 5 ug free - - i.d
3 2 5 ug free - - i.d
Group Three
1 2 10 ug free 1:1 50 i.m
2 2 5 ug free - - i.m
3 2 5 ug free - - i.m
i.p: Intra-peritoneal 
i.d: Intra-dermal 
i.m: Intra-muscular
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to settle down. The cell suspension was decanted into another tube, 
centrifuged for 5 minutes at 1000 rpm and the pellet was resuspended 
in 10ml RPMI medium containing 20% fetal calf serum. The antigen 
was dissolved in 10ml of RPMI medium containing 20% fetal calf 
serum, and then filtered through 0.22u sterile filter .Thymocyte-condi­
tioned media (10 ml) was thawed out and made ready. The antigen 
solution was added to the spleen cells and incubated for 1 hour at 
37° C in humidified atmosphere of 5%C02 . The thymocyte-conditioned 
media was added to the mixture, the mixture seeded in six well tis­
sue culture plate, and incubated in humidified atmosphere of 5%C<92 
for five days.
3.3.4. M onitoring of serum polyclonal response
Mice were bled retro-orbitally or by cardiac puncture after each 
immunization. For groups 1,2 and 3, all mice were bled retro-orbitally 
after each immunization, whereas from group 4, one mouse was bled 
by cardiac puncture after the second and third immunization.
Blood was collected in small Eppendrof polyethylene tubes, kept 
at 4°C overnight, then spun in a bench top centrifuge for 10 minutes. 
The serum was decanted, aliquoted and kept frozen at — 20° C until 
required.
All rats were tail bled after each immunization, and the blood 
treated in the same way as for mice.
Mice and rats sera were screened for antibody to hPTH(l-34) using 
ELISA and liquid phase RIA.
3.4. MAINTENANCE OF MYELOMA CELL LINES
3.4.1. NS1 mouse myeloma cell line
The NS1 myeloma cell line, of Balb/c origin, was grown in RPMI 
medium containing 10% fetal calf serum. The cells initially were 
grown in 10ml tissue culture flask, and the concentration of cells 
kept at 5x 105 cell/ml, then the cells expanded to a 75ml tissue culture 
flask maintaining the same concentration. The cells were allowed to
MOUSE AND RAT MONOCLONAL ANTIBODIES
- 8 4 - CHAPTER 3
grow up to lx 106 cell/ml whenever needed.
The logarithmic growth of the cells were determined by 
incubating lx io5 cells/ml in a 10ml tissue culture flask and counting 
the number of cells for five days.
3.4.2. Y3 Rat myeloma cell line
The rat Y3 cell line was kindly donated by Prof. Milstein. The 
cells were thawed at 37°C and washed in Dulbecco serum free media 
twice, then resuspended in Dulbecco suplmented with 10% FCS, 
glutamine,sodium pyruvate,penicillin and streptomycin.The cells were 
plated in 75cm tissue culture flask and allowed to grow at 37° C in 5% 
CO 2 in humidified atmosphere. Y3 were anchor cells, and so they stick 
to plastic. When the cells fill the confluent of the flask, they start 
growing in suspension,‘those grown in suspension were harvested by 
centrifugation and allowed to continue growth in suspension flasks .The 
other cells were also dissociated from the surface using trypsin EDTA 
at 37° C , and grown in suspension flask. In the early phase the cells 
were incubated in suspension flasks incubated at 37° C without C 02 in 
dry atmosphere. The media was checked every day and the pH neutral­
ized with 10% HC1 whenever it needed adjustment. The media was 
changed every other day or every three days depending on how fast the 
cells were growing. In the early phase they were growing slowly and 
the media was changed every three days. At a later stage the media was 
changed every other day, because the cells were growing faster. The 
cells were monitored by counting them using trypan blue exclusion 
method. These cells were used in the first two rat-rat fusions.
The cells were grown inahot room rather than 37°C incubator pri­
marily because of contamination, and also because the magnetic 
stirrers needed a lot of space in the incubator. At a later stage the cells 
were transferred to C 0 2 incubator, and the suspension flasks were 
kept at 37° C in humidified atmosphere of 5%C02 . The media was 
changed when the nutrients depleted, the cells were pelleted and 
resuspended in new media to a concentration of lx  105 cells/ ml. They
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were always kept at a log phase growth.
3.5. FUSION
3.5.1. Preparation of feeder layer
A mouse which did not recive any immunogen was used. The 
mouse was drenched in ethanol and the spleen taken aseptically and 
immersed in 10 ml RPMI free serum. All other steps were carried 
out in sterile laminar flow cabinet. The spleen was pressed through a 
stainless steel mesh and the clumps of cells were dispersed. The cells 
were transferred to 10 ml centrifuge tube and left standing for 5 
minutes. When the large clumps settled at the bottom of the tube, 
the suspended cells were transferred using sterile plastic Pasteur 
pipette into another 10 ml tube and kept at 37° c  5%C02 until used. 
Usually 4ml out of 10 ml suspension was used per 100 ml of media 
as feeder for fusion or cloning.
Mouse feeder layer was used in both mouse and rat fusions and 
cloning, and also sometimes in growing some slow growing cells which 
needed to be supported by feeder layer.
3.5.2. Fusogen
Polyethelyene glycol,2g (PEG) of M.W 1500 (BDH) was auto- 
claved. Serum free RPMI (2 ml) was added to it while it was still 
warm. The solution was either used immediately or stored frozen at 
—20° C . Before fusion the PEG solution was usually kept at 37° C in a 
water bath for at least half hour.
3.5.3. Preparation of immune spleen cells:
The spleen from mouse/or rat after primary immunization was 
processed in the same way as for the feeder layer. Finally, the total 
number of cells were counted in haemocytometer. When spleen from 
animals after secondary in vitro immunization was used, the cells 
were collected from the tissue culture wells into a 50 ml sterile plastic 
tube, and counted as mentioned above.
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3.5.4. Mouse-mouse fusion:
Preparation of myeloma cell line: The NS1 myeloma cells in a log­
arithmic phase growth were counted and the volume needed was 
transferred into 50 ml sterile centrifuge tube.
The spleen cells were harvested by centrifugation as were the 
myeloma cells. The two cell populations were mixed together in the 
ratio of 5:1 spleen to myeloma cells in 50 ml sterile plastic tube. A 
negative control for each fusion was set up as follows; 50 ul of the 
cell mixture (immune-spleen cells mixed with myeloma cells before 
they were subjected to PEG fusion) were plated in four wells of 24 
well plate. The cells were spun down at 1500 rpm in bench top 
MSE centrifuge. The pellet was drained from fluid using sterile plas­
tic pasteur pipette, and the cells loosened by knocking the edge of the 
tube on the bench. Warmed PEG (0.8 ml) was added slowly with 
continuous shaking over 1 minute. The cells were left standing 
undisturbed for another minute, then 10 ml RPMI free serum was 
added over 5 minutes, and left standing undisturbed for another 10 
minutes. The cells were harvested by centrifugation, and resuspended 
in 100 ml RPMI containing 10% fetal calf serum and 2 times the nor­
mal concentration of HAT.
Plating out: In fusions where 24 well tissue culture plates were
used, 1ml of fusion cell mixture was added to each well, then another 
ml of feeder layer was added. In fusions where 96 well tissue culture 
plates was used, the fusion cells were resuspended in 8-10 ml; and 0.1 
ml was taken in each well, to which 0.1 ml of feeder layer was added. 
The plates were incubated at 37° C , 5%C02 in humidified atmosphere for 
a week before they were inspected for growth, and the media was 
changed.
3.5.5. Rat-Rat fusion:
Preparation of myeloma cell line: The Y3 myeloma cells in a loga­
rithmic phase growth were counted and the volume needed was 
transferred into 50 ml sterile centrifuge tube.
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Immune spleen cells were prepared as above mixed with Y3 rat 
myeloma cells in the ratio of 2:1 spleen to myeloma. The mixture of 
cells were pelleted by centrifugation. The pellet was drained of any 
fluid, and the bottom of the tube was knocked on the bench to release 
the cells. A small volume (0.8 ml)of pre-warmed PEG 1500 was 
added slowly to the cells over 1 minute with slight mixing. The cells 
were left to stand for another 1 minute on the bench, and 10 ml Dul­
becco serum free was added to the cells over 6 minutes with mixing. 
The cells were left standing on the bench for another 10 minutes, 
then they were centrifuged at 1000 rpm for 5 minutes in top 
bench centrifuge,and the pellet was resuspended in 100 ml of Dul­
becco containing 10 % FCS and two times the usual concentration of 
HAT. The cells were seeded in eight 24 well plates. The plates were 
incubated at 37° C in humidified atmosphere o f CO 2 .
3.5.6. Rat-Mouse fusion:
The fusion was carried out as for the rat-rat fusion experiment 
except that the NS1 mouse myeloma cell line was used instead of 
Y3 rat myeloma cell line. The rat spleen cells were mixed with NS1 
mouse myeloma cells in the ratio of 5:1 spleen to myeloma cells, and 
fused using 50% PEG. The fused cells were seeded in 24-well plates 
and incubated at 37°C humidified atmosphere 5% C 02 .
3.5.7. Screening
3.5.7.1. Mouse monoclonal screening
Primary microscopical screening was done after 10 days post 
fusion. The wells which show a positive growth under the micro­
scope were marked and after 2-3 days of media change they were 
assayed using indirect ELISA and liquid phase RIA to examine for 
the presence of antibody specific to hPTH(l-34). The wells which 
prove to be positive in any of the screening assays were expanded in 6 
well tissue culture plates for cloning and freezing. However, a second 
screening was usually done a day before cloning to make sure that the
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cells were still secreting antibody.
3.5.7.2. Rat monoclonal screening
The plates were inspected microscopically after 10 days for 
growth. Those showing growth were further assayed for specific 
antibody to hPTH(l-34) using indirct ELISA and RIA. The screening 
assays were those described in chapter 2.
3.5.7.3. Freezing and thawing of cells
The cells were allowed to grow upto a density of to6 cells/ml in 
10 ml tissue culture fiask, then the cells were pelleted by centrifu­
gation. The pellet was resuspended in RPMI containing 10% fetal 
calf serum and 10% dimethylsulphoxide(DMSO), to the density of 
1—2xl06 cells/ml. The cells were aliquoted in 1 ml portions in 
freezing vials. The vials were frozen at -20°c for 1 hour, then 
transferred to —70°C for another 2 hours, before they were put into 
liquid nitrogen at —196° C . When the cells were needed, a vial was 
taken out of liquid nitrogen and thawed quickly at 37° C . The cells 
were diluted with RPMI 10% FCS and pelleted by centrifugation. The 
pellet was washed once with the same media and the cells cultured in 
a 10 ml tissue culture flask at 37°C , in humidified atmosphere of 5%C<92
3.5.7.4. Cloning
Using the dilution method, the positive clones were counted and 
diluted to the concentration of 50,10 and 5 cells/ml and seeded in 96 
well tissue culture plates. A small volume(100 ul) of the cell 
suspension was added to each well followed by 100 ul of feeder layer. 
The plates were incubated for a week at 37° C 5%C02 in humidified 
atmosphere before they were inspected for positive growth. Those wells 
which showed positive growth of one clone were assayed for antibody 
secretion. Positive antibody secretors were recycled again through the 
same process once more. Aliquotes of the positive clones were stored 
frozen in liquid nitrogen.
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3.6. CHARACTERIZATION OF MONOCLONAL ANTIBODY
3.6.1. Immunoglobulin class
Two methods were used in the determination of immunoglobu­
lin class and subclass of mouse and rat monoclonal antibodies.
Immundifusion: Agarose was supplied by Pharmacia, sheep and rabbit 
anti mouse immunoglobulins and subclasses were from Nordic or Sero- 
tec. 3% PEG 6000 in 1% agarose was prepared as follows: Ig of 
agarose and 3g of PEG 6000 were added to 100 mis of phosphate 
buffered saline pH 7.4 and heated on a hot plate until boiling, then 
the solution cooled down to 56° C . The solution was either kept at 56° C 
until used or aliquoted in 10 ml volumes and stored at 4°C until 
needed. Glass slides,8x8 cm, were cleaned using methanol, and wiped 
with clean tissue. They were put on a levelling table, and 10 ml of 1% 
agarose 3% PEG was poured on the glass slide giving a thickness of 
1.5-1.8 mm. Using the appropriate gel cutters suitable holes were 
cut in the gel. The samples and the typing sera were added to the 
holes and the slides were incubated at room temperature for 24-48 
hours until a precipitin line could be seen. The slides were washed 
with saline for 2 hours, then pressed by covering them with W ath- 
man no.l filter paper and some weight was placed on top of them. 
Finally they were dried and stained using coomassie blue R250 for 5 
minutes and de-stained using acetic acid and methanol until the back­
ground was clear. The slides were then viewed against a bright back­
ground.
Rat monoclonal antibody typing kit was also used in typing rat 
monoclonal antibody. Radial immune diffusion plates as well as typing 
sera were provided in the kit and the procedure recommended by the 
manufacturer was adhered to.
ELISA: The screening ELISA method was used until the stage of 
HRPOase labelled antibody addition. The typing sera, at a dilution of 
1:1000,was added and the plate was incubated at 37°C Tor 2 hours. 
The plate was washed with washing buffer, HRPOase-labelled
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antibody against sheep, goat or rabbit at 1:5000 dilution was added 
and the plate re-incubated at 37° C for another 2 hours. After 
washing, 150ul of substrate was added and the plate was incubated 
at 37° C for 30 minutes. The reaction was stopped by the addition of 
50ul of 2.5M H 2SOa , and the plate read at 490nm in an automatic 
ELISA reader.
3.6.2. Purification of monoclonal antibody
3.6.2.1. Saphacel anion exchange column
Saphacel ready to use pre-swallowed ion exchange resins was sup­
plied by Pharmacia. A 10 cm long column was packed using Pharma­
cia peristaltic pump. The column was then washed extensively with 
phosphate buffer pH 8.6. Samples precipitated by ammonium sul­
phate were used, the concentration of antibody was measured in a 
spectrophotometer at 280nm, and calculated according to Hudson and 
Hay 1980 (Hudson and Hay 1980). The samples were diluted in phos­
phate buffered saline to the concentration of lOmg/ml, further diluted 
in phosphate buffered saline 1:10 and applied to the column at a flow 
rate of 0.5ml/minute. The eluate was monitored at 280nm, until no 
protein was seen emerging from the column. A step gradient was 
prepared from the washing buffer added to it 500mM sodium chloride 
in the other chamber. The gradient ran from 0 to 500 mM N ad at 
0.5 ml/minute, with eluate collected in 5 ml fractions. The fractions 
were assayed for immunoreactivity by ELISA. The fractions with 
good immunoreactivity were pooled together, and dialysed against 
phosphate buffered saline, pH 7.4, overnight with buffer changed three 
times. The dialysate was freeze dried and kept at 4° C .
3.6.2.2« Protein A column
Protein A column was packed and washed with phosphate buffer 
0.03M pH 8.0. The elution buffer was citrate/phosphate buffer pH 
3.5. The samples were either concentrated supernatant or ascitic fluid. 
The column was washed with washing buffer for 1/2 hour and then
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the sample applied containing not more than 2mg total protein. The 
sample was washed with washing buffer until no protein could be 
detected emerging from the column judged by absorbance at 280 
nm. The elution buffer was then applied and fractions collected 
manually where all the protein emerging out of the column in one 
peak was collected in one tube. The fractions were quickly diluted 
with 0.3M phosphate buffer to neutralize the pH, and dialysed against 
phosphate buffer pH 7.4 overnight with three changes of buffer. 
The dialysate was assayed for immunoreactivity, then freeze 
dried and kept at 4°C until reconstituted and used.
3.6.2.3. MONO Q anion exchange column
The MONO Q column was supplied by Pharmacia packed and 
ready to use. The ascites was centrifuged at 3000 rpm for 15 
minutes,and an aliquot of ascitic fluid (200 ul) was filtered through 
0.22 u filter and injected to the column. The column was washed 
with Tris-Hcl buffer pH 7.2. The immunoglobulins were separated 
using a sodium chloride gradient from 0-500 mM. The column was 
run at 1 ml /minute, and fractions of 1 ml were collected. The 
different fractions were assayed for immuno-reactivity using indirect 
ELISA. The fractions which showed good immunoreactivity were 
pooled together and dialysed against PBS pH 7.4 and freeze dried.
3.6.2.4. Ascites production
Using prestaine: Balb/c mice were used as the antibody is of 
Balb/c origin. The mice were primed with the injection of 0.5ml of 
prestaine intraperitoneally and then left for 10 days. The cells 
were grown in 75ml tissue culture flask and counted. The required 
volume was centrifuged to harvest the cells and then resuspended in 
RPMI serum free or PBS to the density of of 1-2* 106 /0.2ml. The mice 
were injected with 0.2 ml of this cell suspension intra-peritoneally. 
When the mice showed maximum enlargement, they were sacrificed by 
cervical dislocation and the ascites sucked using 19G syringe. The 
ascites were centrifuged at 3000 rpm in J6 Beckman refrigerated
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centrifuge for 15 minutes, the pellet was discarded and the superna­
tant aliquoted in 1 ml aliquotes and stored at -2 0 °  C .
3.7. RESULTS
3.7.1. Im m unization
In this study the two main factors affecting the response of an 
animal upon challenge with antigen or immunogen were investigated. 
First, the form of antigen (free or conjugated to a carrier protein) and 
second, the route of immunization. The choice of species was also of 
interest because of lack of information about the two species concerned 
(Balb/c mice and Lou/c rats) from the viewpoint of raising monoclonal 
antibody to PTH-like hormones.
Mice im m unization: The results of Balb/c mice immunization and 
the polyclonal response monitored using ELISA are shown in figures 
3.1- 3.4. The results show that only Balb/c mice immunized with the 
conjugated hPTH(l-34)-BSA responded positively. No difference could 
be seen between the different routes of administration when the free 
hPTH(l-34) was used as immunogen, which suggest that the route of 
immunization may not affect the response of Balb/c mice to hPTH(l- 
34).
Rat im m unization: Rats showed a different result from mice. They 
were tested for the route of immunization using the free fragment 
hPTH(l-34). The sera from rats were assayed using ELISA and RIA. 
The results in figures 3.5-3.7 show that rats responded to the 
immunization with the free hPTH(l-34) only when immunized 
intra- muscularly (i.m). The other routes did not result in any 
detectable antibody in the serum. When the two non-responder groups 
were left for 8-10 weeks and re-immunized with hPTH(l-34) intra­
muscularly only one rat responded.
3.7.2. Myeloma cell lines grow th characteristics
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Figure 3.4: Indirect ELISA serum dilution curve for mouse 
from group four(i.p).
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3.7.2.1 Mouse NS1 myeloma cell line
The growth characteristics of NS1 myeloma cell line was 
demonstrated in figure 3.8. The cultures were maintained under non­
limiting nutrient conditions (i.e the cells were spun and resuspended in 
fresh medium every day). The viability of the cells declined rapidly 
when the cell density approached lx io6 cells/ml regardless of the 
nutrient.
3.7.2.2. Rat Y3 myeloma cell line
The Y3 cell line growth characteristics in stationary phase plastic 
flasks are shown in figure 3.9. The cells were usually thawed and 
grown in plastic flask and then transferred to a spinner. However, 
when the cells were thawed and grown directly in the spinner they 
grew much slower, even when they were seeded in the container 
without spinning for 24 hours as shown in figure 3.10.
The growth of cells at 37° C inahumidified atmosphere of 5% C 02 
in the incubator was better than in the hot room at 37° c  . The viabil­
ity of cells declined slightly in the first two days of suspension as 
shown in Figure 3.10, unlike that observed when plastic flask was 
used( Figure 3.9). When the Y3 cells were grown in a hot room, their 
growth characteristics were the same as those grown in C 02 incubatorsas 
can be seen in figure 3.11.
3.7.3. Fusion
3.7.3.1. Mouse-mouse fusion
The fusion protocol followed was the same in all fusions. The SP2 
myeloma cell line was used only because the NS1 was suspected of 
contamination in that particular fusion. No attempt has been made to 
investigate the fusion efficiency of other myeloma cell lines.
In all fusions, except NOs 1,4,6 and 7, spleen cells from in vivo 
immunization were fused with the NS1 myeloma cell line. In fusions 
NOs 1,4,6 and 7 spleen cells immunized in vitro were used for fusion. 
The results of all fusions are given in Table 3.3.
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Figure 3.9: The growth characteristics of rat Y3 myeloma 
cell line grown in stationary flask.
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The results were calculated in reference to the total number of 
wells seeded per fusion, and the percentage that secreted specific anti­
body to hPTH(l-34) were determined from the first screening assay. 
The clones which continue to produce antibody were much less than 
quoted in the table. The established antibody secreting clones all ori­
ginated from in vitro immunized spleen cells. The clones with low 
O.D at 490 nm in ELISA lost the secretion of antibody shortly after 
the first screening, and in general the clones resulting from primary in 
vivo immunization usually had a low O.D at 490 nm in ELISA than 
these from the in vitro immunization.
3.7.3.2. Rat-Rat fusion
The Y3 myeloma cell line grows well on plastic, but as they stick 
to it, it becomes necessary to use trypsin EDTA to detach them. When 
Y3 cells detached from plastic flask using trypsin-EDTA were used for 
fusion, no growth on microscopical examination or change of media 
colour was observed to indicate positive growth.
When the cells grown in a spinner flask in hot room at 37° C for 
three weeks were used for fusion no positive growth was seen for more 
than six weeks using the criteria stated above. Then it become 
necessary to grow the cells in C 02 incubators in humidified atmosphere. 
However, the fusions carried out with these cells did produce some 
positive growth, though the efficiency was found to be low. Unfor- 
tunatly due to the shortage of time and the constraints of expenses, 
optimization of rat-rat fusion conditions was not persued.
3.7.3.3* Rat-mouse fusion
After the rat-rat fusions were found to be disappointing in
terms of fusion efficiency, the rat spleen cells were fused with the 
mouse NS1 myeloma cell line. The results of all rat-rat and rat-mouse 
fusions are presented in table3.4.
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3.7.3.4. Screening methods
In mouse-mouse fusions, ELISA and RIA for anti-hPTH(l- 
34) antibody were used whenever the amount of supernatant 
available allowed both assays to be run in parallel. When 96 well 
plates were used for plating out the fusion, the amount of superna­
tant was not enough for both assays, and only ELISA was used first 
followed by RIA 3 to 5 days later.
In rat fusions, ELISA and RIA for anti-hPTH(l-34) antibody 
and for bPTH(l-84) antibody were used for screening. As all fusions 
were plated in 24 well plates the amount of supernatant was sufficient 
for both assays to be carried out in parallel.
whjch
ELISA: The positive result was defined as tha tAgave O.D at 490 nm 
higher than twice the negative control. All the mouse-mouse fusions 
were assayed and the positive clones selected by ELISA. Both methods 
of ELISA were used, method A was used in all fusions, while method 
B only in the last two fusions and in further work with the anti­
body. Because of the background, method B usually relied on for 
the selection of positive clones, eventhough sometimes the blanks gave 
a high result because of the immunoglobulin type of the antibody. 
Table 3.5 gives an example of the results of both methods.
Rat fusions were assayed using ELISA method B. In all assays the 
positive result is taken as that gave O.D at 490 nm higher than twice 
the negative control and higher than the blank. When the immunoglo­
bulin class of the antibody is known to have higher affinity to the solid 
phase the blank becomes higher and the negative control criteria is used, 
because the cut off point between negative and positive becomes 
difficult to establish. Table 3.6 gives an example of rat fusion ELISA 
results.
which
RIA: The positive was taken as thatAgave percentage binding of at least 
2% higher than the NSB. The screening of antibody to hPTH(l-34) 
and bPTH(l-84) was the same with respect to procedure, solutions and 
buffers used.
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Table 3.5
Mouse monoclonal antibody screening using ELISA.
Clone ELISA method A O.D at 490 nm ELISA method B O.D at 490 nm
Test Blank Test
4/PTH/NS1 1.025 0.765 1.465
4/PTH/NS2 1.265 0.629 1.072
4/PTH/NS3 1.023 0.712 1.000
5/PTH/SP1 1.325 0.427 1.205
5/PTH/SP2 1.252 0.814 1.100
RPMI 10% 0.095 0.098 0.110
N.M.S IK 0.325 0.275 0.262
2° Ab 0.055 0.062 0.070
Substrate 0.032 0.042 0.058
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Table 3.6
ELISA results of some rat monoclonal antibody
Clone ELISA method A O.D at 490 nm ELISA method B O.D at 490 nm
Test Blank Test
R/PTH/6 1.225 0.965 1.265
R/PTH/9 0.965 0.729 0.972
R/PTH/14 0.823 0.712 0.835
R/PTH/22 1.125 0.627 1.325
R/PTH/22,2 1.052 0.714 1.003
RPMI 10% 0.125 0.098 0.105
N.R.S IK 0.225 0.175 0.252
2° Ab 0.035 0.062 0.060
Substrate 0.022 0.042 0.038
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In mouse-mouse fusion the phase separation was accomplished 
using donkey anti-mouse serum neat or diluted 1:10 as well as 
dextran coated charcoal. The incubation time of the phase separation 
was also varied from 3 hours at 4°C to overnight at 4°C for the 
anti-mouse serum. No binding was seen in any of the spe cimens from 
mouse fusions. Those found positive by ELISA also showed no binding 
even when they were grown to stationary phase (i.e when the cells 
were allowed to grow until the nutrients exhausted and the cells 
started to die) when the antibody concentration expected to be max­
imum in the supernatant.
In rat fusions the phase separation was also accomplished using 
donkey anti-rat serum neat and diluted 1:5. Screening the supernatants 
for both hPTH(l-34) and bPTH(l-84) antibody at least three times 
did not result in any positive clones and the maximum binding 
observed was negligible around 2%. Table 3.7 gives a summary of the 
findings from assay of products from mouse and rat fusions.
3.7.3.5. Characterization of monoclonal antibody
The ELISA method is more sensitive than immunodiffusion, How­
ever, the crossreactivity of the different antibody sometimes results in 
a high background. The results using ELISA of four clones of mouse 
monoclonal were shown in figure 3.12 The immunoglobulin class and 
subclass of the other clones were shown in table 3.8. In mouse immu­
noglobulin typing experiments,predpitin lines were visible after 24 
hours incubation at room temperature.
The class and subclass typing of rat monoclonal antibodies are 
shown in table 3.9, and their typing results from ELISA are shown in 
figure 3.13. In rat immunoglobulin typing assay, the precipitin lines 
were visible after 48 hours incubation at room temperature.
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Table 3.8.
Ig class and subclass of mouse monoclonal antibody clones
Clone name Ig class and subclass
4/PTH/NS1 IgGl
4/PTH/NS2 IgGl
4/PTH/NS3 IgG2b
4/PTH/NS4 IgGl
4/PTH/NS5 IgG2a
5/PTH/SP1 IgG2b
5/PTH/SP2 IgGl
5/PTH/SP3 IgGl
5/PTH/SP4 IgG2b
5/PTH/SP5 IgG2b
5/PTH/SP6 IgG2a
5/PTH/SP7 IgG2a
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Table 3.9
Ig class and subclass of rat monoclonal antibody clones
Clone name Ig class and subclass
R/PTH/6 IgM
R/PTH/9 IgM
R/PTH/14 IgM
R/PTH/22
JIst>J0 
! 
»—
t
!
R/PTH/22,2 IgM
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3.7.3.6. Purification of monoclonal antibody
The elution profile of mouse antibody from each column has been 
shown in figure 3.14, 3.15, 3.16. The finding from SDS-PAGE 
analysis of the purified antibody from protein A column are shown in 
plate 3.1. The results of the purification of rat monoclonal antibodies 
using MONO Q anion exchange column and gel filtration are given in 
Figures 3.17 and 3.18 and the SDS-PAGE analysis data in plate 3.2.
3.8. DISCUSSION AND CONCLUSION
3.8.1. Mouse monoclonal antibodies
Balb/c mice have been commonly used in the production of 
monoclonal antibodies,although the immunization schedules seem to 
vary a great deal among workers in the field. A common route of 
immunization is the intrapertoneal injection; other routes have been 
used less frequently, only after having been shown to produce a better 
response.
The immunization schedule followed in this project was to investi­
gate whether the response of Balb/c mice to hPTH(l-34) is affected 
by the route of immunization, and also the form of antigen free and 
conjugate. It is known that the conjugation enhances the immune 
response and yields a high affinity antibody. However, Nussbaum 
investigated the conjugation of hPTH(l-34) to a carrier protein and 
found no difference in response between the two forms (Nussbaum et 
al., 1985). Van de Walls (Van De Walle et al., 1983) also used Balb/c 
in the development of monoclonal antibody to PTH. The mice 
responded, and antibody was of the IgG.
In the present project the doses were a lot lower than what pre­
vious workers used. The mice were injected with lower doses in order 
to enhance the selection of more specific response and higher affinity 
antibodies.
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Figure 3.15: Protein A affinity column purification of mouse 
monoclonal antibody 5/PTH/SP2.
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Plate 3.1: SDS-PAGE analysis of protein A purified 
mouse monoclonal antibodies, (a) ascites (b) 
4/PTH/NS1 (c) 4/PTH/NS3 (d) 5/PTH/SP1 (e) 
5/PTH/SP2. Left and right hand sides is the molecu­
lar weight marker. 7.5% acrylamide under reducing 
conditions was used according to the method of 
Campbell 1984.
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Figure 3.17:(a) Mono Q anion exchange elution profile of rat 
monoclonal antibody R/PTH/6. (bj The ELISA immu- 
noreactivity assessment of the fractions.
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Figure 3.18: (a) Gel filtration of Mono Q purified rat mono­
clonal antibody R/PTH/6. (b) The ELISA immunoreactivity 
assessment of the fractions from gel filtration.
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Plate 3.2: SDS-PAGE analysis of affinity purffied and 
gel filtered ra t monoclonal antibodies, (a) molecular 
weight m arker (b) (c) (d) (e) (f) and (h) are non 
purffied supernatant from R/PTH/6, R/PTH/9, 
R /PTH/2, R/PTH/22, R/PTH/14 and R/PTH/22,2 
respectively, (g) Mono Q purffied R/PTH/6 (i) Mono Q 
and gel filtered R/PTH/6. 7.5% acrylamide under 
reducing conditions was used according to the method 
of Campbell 1984.
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The results show that hPTh(l-34) has to be conjugated in order to eli­
cit detectable antibody response in Balb/c mice. The route of 
immunization seems to be not particularly important.
3.8.2. Rat Monoclonal Antibodies
The species difference in regard to immune response is a well 
known phenomenon, as is the individual differences between members 
of the same species. The rats immunized with the free hPTH amino- 
terminal (1-34) fragment, showed a response that tended to be related 
to the route of immunization. They only responded when immunized 
through the intra-muscular route. This is illustrated again when rats 
immunized intra-dermally produced no response until after they were 
re- immunized intra-muscularly. In this latter group some animals 
might have developed tolerance, one rat responded when re-immunized 
intra-muscularly, whereas the remaining three did not respond. They 
had been exposed to the antigen before, and suppressor T cells might 
have been activated to prevent the B cell response.
The mouse fusion technique is principally that used by Milstein 
in 1975 with the improvements made to it over the last 10 to 13 
years. The specific efficiency is notably low, and the underlying reason 
might be associated with any step or steps in the procedure. The 
secondary in-vitro immunization evidently improved the specific 
efficiency, and the clones stabilized were originally derived from 
secondary in-vitro stimulation.
The monoclonal antibodies were all of the IgG class, an indi­
cation that primary stimulation of the B lymphocytes may have pre­
ceded the in-vitro stimulation.
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CHAPTER 4
GOAT POLYCLONAL AND MONOCLONAL 
ANTIBODIES TO hPTH(l-34)
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4.1. INTRODUCTION
Antisera to PTH have been raised in various animal species, 
including guinea pigs (Berson et al., 1963), chicken (Reiss and 
Canterbury 1968, Chase and Slatopolsky 1974, and Vieira et al., 1986), 
goat (Fisher et al., 1974, Manning et al., 1977) and sheep (Wood et al., 
1980, Mallette et al., 1981). The tendency for immunological recogni­
tion of certain regions of PTH amongst different species certainly does 
exist.
The choice of animal for immunization is usually determined by 
the cost of the animal, cost of its maintenance, the longevity and 
possibly the species if there is clear cut evidence that certain species 
respond better than others to the peptide hormone region selected. In 
general almost all species will respond and some antibody will be 
detected in the serum of the animal. However, the amount of serum 
obtained at each bleed, the titre and the affinity of the antibody 
are all of importance to the use of the antibody and the choise of 
animal especially because the bleeds tend to differ from each other 
markedly. The titre and affinity of the antibody will determine the 
type of assay in which it can be used. Although most assays favour 
the use of high affinity antibodies, in some assays even an antibody 
with a moderate or low affinity can be used provided a large amount of 
the antibody is available.
Large animals are usually preferred because of the long life 
expectancy and the large amount of serum available. On the other 
hand antibodies of high affinity and titre are usually obtained from 
small animals like rooster and guinea pig. The large amount of 
blood obtainable from the large animals also can be used in the pro­
duction of monoclonal antibodies. In small animals where no myeloma 
cell lines is available the only source of B-lymphocytes is the spleen; 
this limits the use of the same animal in the production of both mono- 
and polyclonal antibodies. Large animals in the other hand are more 
suited for the dual purpose, as large amounts of blood can be taken
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and the development of cell lines suitable for fusion have been found 
to be possible (Groves et al., 1987)
Since the introduction of monoclonal antibodies in 1975 (Kohler
and Milstein 1975), the interspecific cell hybridization has been
increasingly used in attempts to produce monoclonal antibodies from
species for which myeloma cell lines are not readily available. Fusion
between rat spleen cells and mouse myeloma cell line has been used to
produce monoclonal antibodies to mouse antigens (Trowbridge
1978). Human monoclonal antibodies were also produced using the
same approach in the early stages (Scwaber and Rosen 1978). However,
beenthe extent to which the human modelhas*studied, the inves­
tigation of stable human cell lines and examination
of the literature devoted to this subject, indicate it may be
difficult to develop myeloma cell lines from any less 
studied species.
Nonetheless, with the modern developments in biotechnology 
involving the production of proteins in-vitro, and the development of 
an in-vitro large scale production systems for monoclonal antibodies, 
the use of cross-species fusion and the subsequent production of 
monoclonal antibodies in-vitro look- feasible.
Early interspecific fusions of rat and human with mouse myeloma 
cell lines, prompted large scale use of this approach in the pro­
duction of monoclonal antibodies from other species. Immortalization 
of sheep cell for the production of monoclonal antibodies was first 
attempted in 1981 (Tucker et al., 1981). This was done by fusing the 
ovine lymph node or spleen cells with mouse myeloma cell lines.
Loss of immunoglobulin production occurred despite the good growth 
of hybridoma in culture. Later, a technique used in human fusion 
to increase the efficiency of fusion and stabilize the resulting 
hybridoma (Ostberg and Pursch 1983, Teng et al., 1983) was 
adapted successfully with other species (Tucker et al., 1984, Anderson 
et al., 1986, Groves et al., 1987, Tucker et al., 1987, Groves et al.,
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1988). The use of interspecific hybridoma after their sensitization 
to aminopterin as fusion partners overcomes some of the problems 
of interspecific fusion, not least the stability of cell lines pro­
duced. This approach have been used to produce human, chimpanzee 
(Van Meurs and Jonker 1986), cattle (Groves et al., 1987) and sheep 
aiitibodies. The use of a second and third generation of refusion have 
also been used in the production of bovine antibodies (Tucker et al., 
1987). All fusion reported to date depend on the incorporation into one 
cell of gene of two different species (i.e mouse and sheep) but not 
three.
4.2. MATERIALS AND METHODS
4.2.1. Conjugation of hPTH( 1-34)
hPTH(l-34) from Sigma was conjugated to Key Holy Lim­
pet hemocyanin using the glutaraldehyde method as described in 
chapter 3. hPTH(l-34); 52 ug was dissolved in 1 ml of sterile 
water,added to 9 ug of Key Holy Limpt hemocyanin after activation 
with 2.5% glutaraldehyde. The solution was mixed for few seconds 
and then mixed with non ulcerative adjuvant in the ratio of 1:1.
4.2.2. Immunization
A goat was immunized with hPTH(l-34), in the free form. 
After two months a booster injection was given. Two further booster 
injections were given with two months interval between them. The 
conjugated hPTH(l-34) was then used for boosting to enhance the 
antibody titre. The last boost was 50 ug hPTH(l-34) given in the 
free form. Table 4.1 describes the immunization schedule and materials 
used.
4.2.3. Monitoring of serum antibody
The goat was bled 9-10 days after each immunization and every 
two weeks thereafter. The blood collected from the jugular vein was 
kept at 4°C overnight,then the blood was centrifuged in a Beckman J6B
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refrigerated centrifuge at 3000 rpm for 30 minutes at 4 °c  . The serum 
was decanted and sodium azide was added to it to a concentration of 
0.1%. The serum was stored at 4°C . The bleeds were assayed using 
both RIA and ELISA as described in chapter 2.
4.3. CHARACTERIZATION OF ANTIBODY
4.3.1. Specificity
The goat serum was assessed for the specificity for hPTH(l-34) 
using the following peptides:
RH1 (hPTH(9-15)), RH2 (hPTH( 18-24)), RH3 (hPTH(24-28)), RH4 
(hPTH(28-34)) all synthesised in the Chemistry department,University 
of Surrey. hPTH(39-84), hPTH(l-84) obtained from Markiting Asocis- 
tion. LH, GH, TSH, Prolactin and hCG all supplied by the National 
Institute of Biological studies. The bleeds tested were G8/19187 (the 
first bleed after the 2 nd immunization) and G8/11687 (the first bleed 
after the 4th immunization).
In RIA a standard curve was constructed, and different 
concentrations Ipg/ml-lOOug/ml of the four small N-terminal 
peptides,the C-terminal(39-84) and lug/m l-lpg/m l of the whole 
molecule hPTH(l-84) were allowed to react with the antibody for 3 
days. The labelled hPTH(l-34) was then added and the tubes were 
incubated for a further 3 days. The antigen antibody complex was 
precipitated with second antibody and PEG 6000, and the pellet 
counted for 100 seconds in multigamma counter.
ELISA PVC plates were coated with lOOug/ml of the four small 
peptides RH1, RH2, RH3, RH4 and the C-terminal(39-84), and with 
2ug/ml of the whole molecule(l-84) and hPTH(l-34), and the plates 
incubated at 4°C overnight. After washing and blocking of the free 
sites, the serum, diluted to give absorbance of 0.75 at 490 nm, was 
added to the plates and the incubation continued overnight at 4° C . 
The plates were washed again and the bound antibody was visualized 
using HRPOase second antibody and the substrate.
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Other unrelated peptides were also tested using the same ELISA 
and RIA methods. In ELISA a concentrations between 0.5 and 2 
ug/ml were adsorbed on PVC ELISA plates and the antibody allowed to 
react to them. The bound antibody was revealed with enzyme 
labelled second antibody and substrate.
4.3.2. Affinity constant
The two bleeds chosen for cross reactivity were also used for 
affinity constant determination. The scatchard plots were constructed 
from the results of standard curves, where the concentration of 
labelled hPTH(l-34) added per tube was also calculated. A computer 
program has been used for plotting these results and calculating the 
various constants.
4.3.3. Displacement and standard curves:
The displacement of bound hPTH(l-34) was assayed using ELISA 
and RIA. In ELISA the bound hPTH(l-34) was displaced using the 
same solid phase hPTH(l-34). The antiserum was diluted serially and 
200 ul of each dilution was incubated with different concentrations 
of hPTH(l-34) overnight at 4°C . Then 200 ul of the mixture was 
transferred to a PVC plate coated with 2 ug/ml hPTHl-34) and the 
plate incubated overnight at 4° C  . After washing the bound antibody 
was visualized using HRPOase labelled second antibody and substrate.
In liquid phase RIA the serum was serially diluted and 100 ul of 
each dilution incubated with different concentrations of hPTH(l-34) 
and incubated overnight at 4° C . The next day the labelled 
hPTH(l-34) ,10000 cpm in 100 ul, was added to all tubes. The incuba­
tion continued overnight at 4°C . The bound antigen antibody was pre­
cipitated using second antibody and PEG 6000 and the pellet counted 
using multigamma counter.
The standard curve was constructed using liquid phase RIA. The 
titre was chosen from the antiserum dilution curve and the assay was 
set up as follows:
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To duplicate LP3 tubes 100 ul of anti-hPTH(l-34) serum diluted 
1:1200 (at which 50% binding of } 25I  -hPTH(l-34)is obtained ) was 
added followed by 100 ul of dilution buffer. Standard hPTH(l-34) was 
diluted to give a concentration between lpg/m l and lug/m l and 100 ul 
of each concentration was added to the appropriate tubes. The tubes 
were mixed and incubated at 4°C overnight. The labelled hPTH(l-34), 
10000 cpm in 100 ul, was added to all tubes, the tubes mixed and 
incubated overnight at 4°c . The bound antigen-antibody was precipi­
tated with second antibody and PEG 6000. The pellet was counted in 
multigamma counter.
4.4. GOAT MONOCLONAL ANTIBODY
4.4.1. Myeloma cell line
The myeloma cell line was developed by Mr B.Morris and his 
co-workers in the Biochemistry Department University of Surrey. The 
murine-ovine myeloma cell line was selected from fusion of NS1 with 
ovine B lymphocytes. This cell line was grown in 8 azaguanine and 
developed for fusion with ovine B lymphocytes.
One vial of cells was thawed out quickly in a 37° C water bath, 
the cells were washed in RPMI 10 % FCS twice and resuspended in 10 
ml of RPMI 10 % FCS, and plated in 20 ml tissue culture flask. The 
cells were maintained at log phase growth for at least a week before 
fusion.
4.4.2. Blood collection
The goat was immunized with 100 ug of unconjugated hPTH(l- 
34) in incomplete adjuvent, and boosted with 50ug of unconjugated 
hPTH(l-34) as described above. Three days after boosting, 200 ml of 
blood was collected into 10 ml heparin vacutainer tubes, the tubes 
were mixed thoroughly with the anticoagulant, and the mixing con­
tinued until the blood was ready to be used.
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4.4.3. Lymphocyte separation
The blood was pooled in two 200 ml dragons, and diluted 1:1 v /v  
with sterile phosphate buffered saline pH 7.4 (Flow laboratory). Then 
the lymphocytes were separated by density gradient centrifugation on 
lymphopaque (Nyegard,UK). The lymphocytes were washed twice 
with Hank’s balanced salt solution, and repelleted by centrifugation. 
The pellet was resuspended in RPMI 10 % FCS. The lymphocytes were 
counted using trypan blue.
4.4.4. Fusion and plating out
Preparation of mouse feeder layer: the spleen of unimmunized 
mouse was taken aseptically, and processed as described in chapter 3.
Preparation of Myeloma cell line: the myeloma cell line was grown 
in a log phase. The day before fusion the cells were counted using 
trypan blue, and they were seeded at 5x 105 cells/ml. On the day of 
fusion, the cells were counted again. The required volume was centri­
fuged, and the cells were resuspended in fresh medium and kept in the 
incubator until needed.
4.4.5. Goat-Heteromyeloma fusion
The goat lymphocytes were divided in two parts. One half was 
fused with NS1 mouse myeloma, and the other half fused with ovine- 
murine heteromyeloma.
The goat lymphocytes were prepared as mentioned above. They 
were counted, and centrifuged at 1000 rpm for 5 minutes. The pellet 
was resuspended in the heteromyeloma medium, and mixed giving a 
ratio of 2:1 for lymphocytes to heteromyeloma cells. The mixture was 
pelleted by centrifugation at 1000 rpm for 5 minutes. The cells were 
drained of any solution using a Pasteur pipette. The edge of the tube 
was knocked on the bench to release the cells. An aliquot of pre­
warmed 50 % PEG 1500 (0.8 ml) was added slowly to the cells over 
1 minute. The cells were left standing without disturbance for 
another minute, then diluted slowly with 10 ml of serum free RPMI
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over 6 minutes. The mixture was left to stand on the bench for 
another 10 minutes without disturbance. The cells were pelleted by 
centrifugation at 1000 rpm for 5 minutes, and resuspended in 200 ml 
of RPMI 10 % FCS containing 2X HAT. The cells were plated out in 
eight 24-well tissue culture plates, 1ml per well. Feeder layer(lm l) 
was added to each well and the plates were incubated at 37° C in 
humidified atmosphere containing 5% C 02 .
4.4.6. Goat-Mouse NS1 myeloma fusion
The mouse NS1 myeloma cell line was prepared as described in 
chapter 3. On the day of fusion the cells were counted, then pelleted 
and resuspended in fresh medium. The goat lymphocytes were 
prepared and counted as mentioned above. The lymphocytes were 
mixed with NS1 in the ratio of 5:1 lymphocytes to NSl,and pelleted 
by centrifugation. The cells, drained of any liquid, were released by 
knocking the edge of the tube on the bench. The fusion was carried 
out as for goat-heteromyeloma. The cells were seeded in eight 24 
well tissue culture plates, and incubated at 37°C in humidified atmo­
sphere containing 5% C 02 .
4.4.7. Screening
The plates were screened primarily under the microscope. Those 
which showed positive growth were subjected to further assays to 
select for the specific antibody producers. As for rat and mouse 
fusions before, ELISA and RIA assay systems were used. The 
methods were the same as that described in section 2.2.0 and 2.3.0. 
ELISA and, RIA liquid phase for the hPTH(l-34) and RIA liquid 
phase for bPTH(l-84) were used to screen for antibody production.
For ELISA, donkey anti goat IgG was supplied by Guildhay 
Antisera Ltd and was used at 1:8000 dilution. Antigen and antibody 
incubations were all carried out overnight.
In RIA for hPTH( 1-34), three assays were run together, one 
included neat donkey anti goat serum , the second donkey anti goat
GOAT POLY- AND MONOCLONAL ANTIBODIES
- 136 - CHAPTER 4
serum diluted 1:10 and in the third type dextran ~ coated charcoal was 
used for separation.
In liquid phase RIA for bPTH(l-84), two assays were run 
together, the first with donkey anti goat serum diluted 1:10, and the 
second using dextran coated charcoal.
The cells were screened three times, and the positive wells in 
more than one assay in the first screening were cloned. Those wells 
which showed a positive growth were assayed for anti-hPTH(l-34) and 
anti-bPTH( 1-84) specific antibodies. The positives were expanded and 
cloned using limiting dilution method.
4.4.8. Cloning
The cells were cloned using the limiting dilution method. Each 
positive well was cloned in two 96 well tissue culture plates. Three 
different concentrations of cells were used, 50 cells/ml, 10 cells/ml and 
5 cells/ml. The 5 cells/ml concentration was cloned and plated in one 
96 well tissue culture plate, the other two concentrations were plated 
each in half plate. In the wells the cells were mixed with the mouse 
feeder layer,and the plates were incubated at 37° C in humidified atmo­
sphere with 5% CO 2 • The plates were inspected for growth after 
seven days. Those containing one clone were tested for specific 
antibody secretion.
4.5. RESULTS
4.5.1. Serum polyclonal antibody
The bleeds from the goat were tested for hPTH(l-34) antibody 
using both liquid phase RIA, and ELISA. As expected, after each boost 
the titre of the bleeds increased to a maximum, then decreased. How­
ever, the first bleed after each boost gave the highest titre and, then 
either the titre sustained for a few weeks and started to drop down, 
or went down immediately. The titre after the first boost was 
1/1200, and in all other bleeds the titre never went higher than 
that.Figure 4.1 shows a typical change of titre after the first boost.
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Figure 4.2 shows the titre of all bleeds. Figure 4.3 shows the dilution 
curve using ELISA.
The standard curve and results from displacement studies are 
shown in figure 4.4 and 4.5 respectively. There is a small effect of 
prolonged incubation upon antiserum dilution curve,as can be seen in 
figure 4.6.
4.5.2. Characterization of antibody
Specificity : The specificity of the two best bleeds were tested. 
The bleeds were chosen according to the titre.
Different fragments of hPTH(l-34) as well as other unrelated 
peptides were used. The small fragments within the N-terminal 
sequence were used to map the antigenic determinant. While the 
whole molecule (1-84) and the C-terminal (39-84)PTH along with 
other unrelated peptides were used to test the specificity of the anti­
body.
The cross-reactivity of goat anti-hPTH(l-34) antibody has been 
tested using ELISA and RIA. Figure 4.7 shows the cross-reactivity of 
fragments within the N-terminal fragment (1-34), C-terminal (39- 
84) and the whole molecule using ELISA. The binding of antibody to 
h P T H (l-34) has been taken as 100% binding, while other fragments 
binding calculated as a percentage of that of hPTH(l-34). The results 
of RIA were shown in figure 4.8 a,b and c. It can be seen that the 
cross-reactivity with the whole molecule is almost 100% in RIA, while 
only 10% in ELISA. It seems that the antibody will not differentiate 
between the whole molecule and the N-terminal (1-34) in RIA, but 
once the whole molecule is adsorbed to solid phase support (ELISA 
plates) the antibody will bind to it minimally.
The cross-reactivity with other peptides was minimal in both 
ELISA and RIA. The cross-reactivity was 0.1-1 percent in ELISA and 
less than 0.5% in RIA.
Association constant; The affinity constant of the same two
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Figure 4.2: RIA titre of goat bleeds.
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Figure 4.4: hPTH(l-34) RIA standard curve, using goat 
bleed G8/11687.
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bleeds used previously for cross reactivity were determined on the basis 
of scatchard plot. From the RIA results the affinity constant was 
found to be 5x 1091/mol for both the bleeds.
4.5.3. Monoclonal antibody
The volume of goat blood used (200 ml) yielded 2xl08 lympho­
cytes, of which one half was fused with ovine-murine heteromyeloma, 
and the other half fused with mouse NS1 myeloma cell line. The 
screening started after 12 days, primary microscopic screening 
revealed 100 % growth with a mean of 5 clones in each well of the 
goat heteromyeloma, and 100 % growth with a mean of 3 clones in 
each well in goat-mouse fusion.
After the microscopic screening the media changed, and after 
three days screening for specific antibody to hPTH(l-34) and bPTH(l- 
84) was carried out using liquid phase RIA and ELISA.
In RIA screening the goat-heteromyeloma resulted in five clones 
positive to hPTH(l-34). The wells were assayed three times and in each 
the cells were found to secrete antibody to hPTH(l-34). The antibody 
was detectable by all three methods used to precipitate the antibody- 
antigen complex (neat donkey anti-goat, donkey anti-goat diluted 1:10 
and dextran coated charcoal). The results are shown in figure 4.9.
The antibody did not cross-react with bPTH(l-84), when the 
same antigen was used as radiolabelled ( ,125/  -bPTH(l-84)). The use 
of both donkey anti-goat and dextran coated charcoal to precipitate 
the antigen-antibody complex showed no binding. The results of both 
fusions are summarised in table 4.2.
It was noted that the goat-heteromyeloma hybridoma clones 
were bigger and grew faster than the goat-mouse hybridoma clones. 
In general, the clones were much smaller than mouse-mouse clones.
The media was changed three days before screening, and the 
supernatant taken was used in all assays. All the positive clones stoped 
secreting the antibody six days after the first screening.
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4.6. DISCUSSION AND CONCLUSION
4.6.1. Polyclonal antibody
The goat was commonly used in the production of polyclonal 
antibody to hPTH. It is considered to be a good responders and recom­
mended for use in PTH antibodies (Mallete 1983). In this study the 
immunization regimen adopted proved to be effective; the goat 
responded to the free fragment only and as low as 100 ug, used in the 
first immunization, was enough to elicit a good response. The 
specificity of the antibody however confirms the recent claim of an 
antigenic determinant within the 18-25 amino-acid sequence of this 
fragment (Veiere et al., 1987). Hence it is not surprising that the 
antibody cross-reacts 100% with the whole molecule (1-84), but 
shows no binding to 39-84 amino- acid sequence. The discrepancy 
between ELISA and RIA cross reactivity results might be arrtibuted to 
the different principle underlying each technique. The presentation of 
the antigen is completely different in these two assay systems. While 
the antibody binds hPTH(l-84) in solution where all
antigenic determinants are available, in ELISA the adsorption to PVC 
plate restrict the determinants available for binding. Other peptides 
unrelated to PTH did not bind the antibody in either ELISA or liquid 
phase RIA.
4.6.2. Monoclonal antibody
Many species have been used in cross-species fusion. This is the 
first report of goat-mouse fusion, and an attempt to use goat in cross­
species heteromyeloma fusion.
All other cross-species fusions reported before were found to 
lose quickly their non-myeloma chromosomes; the goat-mouse fusion 
in the present study is no exception. The fusion was successful, and 
100% growth was achieved. However, specific clones producing anti­
body to hPTH(l-34) has not been detected. This is not surprising 
since even in the mouse and rat fusions where compatible cells are used
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this can happen. Moreover, it is encouraging in that improvements 
in the specific efficiency of fusion is easier to contend with than fusion 
efficiency. These cell lines can also be used as heteomyeloma in future 
fusions for the stabilization of cell lines.
The loss of foreign chromosomes noted in all cross-species fusion 
and the production of stable clones was shown to be achieved by the 
use of heteromeyloma as fusion partners (Tucker et al., 1987, Tucker et 
al., 1985, Groves et al., 1988, Groves et al., 1987, Teng et al., 1985). 
Moreover, the use of primary, secondary and tertiary hetro-hybridoma 
(heteromyeloma) was also found to be possible (Tucker et al., 1987). 
However, so far the possibility of heteromyeloma of two species to be 
crossed with a third one has not been tried. In this study a hetero­
myeloma of ovine-mouse was fused with goat blood lymphocytes. The 
resulting hybridomas demonstrated the production of specific antibody 
to hPTH(l-34). The cell lines also showed a very good specificity in 
that they did not appear to recognise the same fragment adsorbed to 
PVC ELISA plate nor to bPTH(l-84) in liquid phase RIA.
GOAT POLY- AND MONOCLONAL ANTIBODIES
- 153 - CHAPTER 5
CHAPTER 5
APPLICATION OF 
MON OCLONAL ANTIBODIES
APPLICATION OF MONOCLONALS
- 154- CHAPTER 5
5.1. INTRODUCTION
In contrast to polyclonal antibodies, monoclonal antibodies offer 
selectivity of a finer degree, in conjunction with the homogeniety and 
availability in large quantities. This allows easier standardization of 
immunoassay procedures and their in the laboratory on a wider scale. 
Furthermore, the monoclonal antibody also made it possible to expand 
the applications of antibodies using various combination of their pro­
perties, and the design of novel assay systems. A summary of these 
advantages is given in table 5.1.
The clinical, biological and other uses of monoclonal antibodies 
have been extensively reviewed (Foster 1982, Hubbard 1983, Davis and 
Rao 1984, James et al., 1984). In this study the antibodies to hPTH(l- 
34) were intended for use in immunoassay and immunocytochemical 
investigation.
5.2. IMMUNOCYTO CHEMISTRY
5.2.1. M aterials
Affinity purified donkey anti-mouse HRPOase and Alkaline 
phosphatase-labelled IgG was obtained from Guildhay antisera Ltd. 
Affinity purified sheep anti-mouse alkaline phosphatase labelled IgG 
was supplied by Nordic. Naphthol AS:B1 phosphoric acid and Fast 
Red TR were supplied by Sigma. 3,3’-Diaminobenzidine tetrahydro- 
chloride (DAB) was obtained from BDH.A11 other chemicals were 
of analytical grade.
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Table 5.1
comparison of monoclonal and polyclonal antibodies properties
Property Polyclonal antibody Monoclonal antibody
Concentration of 
immunoglobulin
lOmg/ml 0.1-10mg/ml
Concentration of 
desired antibody
0.1-1.0mg/ml 0.1-1.0mg/ml
Reproducibility variable from 
batch to batch
absolute
Cross-reactivity common rare,unless the same 
antigenic determinant 
present in other 
antigens
Supply limited for each 
animal and each 
bleed
unlimited
Properties spectrum of all 
immunoglobulins 
with behavior 
varies, as it is spec­
trum of all immu­
noglobulins
one class and 
subclass,with pre­
selected properties by 
screening
Cost relatively cheap expensive
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5.2.2. Buffers
Veronal acetate buffer, pH 9.2: 0.9715 g of sodium acetate 
(trihydrate), 1.4715 g of sodium barbitone and 2.5 ml of 0.1M HC1 
were dissolved and made up to 250 ml with decarbonated distilled 
water.
Tris-HCl buffer pH 7.6: Tris(hydroxymethyl)aminomethane 9.1
g, sodium chloride 25.5 g were dissolved in 750 ml of distilled water 
and mixed thoroughly. The pH was adjusted to 7.6 using 1.0M HC1 
and the volume completed to 1000 ml.
Citrate acetate buffer pH 5.0: 5.3 g of citric acid was dissolved in 
500 ml of distilled water, and 12.0 g of ammonium acetate was dis­
solved in 3 litres of distilled water. The citric acid solution was added 
slowly to the ammonium acitate solution until the pH was 5.0.
Peroxidase blocking solution: 120 ml of hydrogen peroxide 30% 
v /v  was added slowely to 200 ml of methanol. The solution was used 
within a week, and not more than twice.
Alkaline Phosphatase Substrate solution: Naphthol AS:B1
phosphoric acid (sodium salt), 5mg, was dissolved in 3 drops of 
dimethylformamide (BDH), and 5mg Fast Red TR was dissolved in 10
ml veronal buffer pH 9.2. The naphthol solution was added to the
Fast Red solution, mixed, and filtered. This was usually prepared just 
before use.
Substrate solution for Horseradish peroxidase: 125 mg of DAB 
were dissolved in 340 ml of citrate acetate buffer pH 5.0. The DAB 
dissolved in small volume of buffer first, then the rest of the buffer 
volume added, and the solution was sonicated. This reagent was 
prepared just before use each time.
5.2.3. Tissue samples
Formalin-fixed tissue sections of human parathyroid gland
adenoma and/or carcinoma, chief cell carcinoma, were obtained during 
surgery or as an autopsy samples. These were supplied ready for use
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(Courtesy of Mr Peter Jenkins, Pathology, Royal Surrey County 
Hospital)
5.2.4. Procedure for Alkaline phosphatase staining
The tissues were dewaxed by taking them through xylene and 
different concentrations of alcohol and finally to water. The tissues 
were then incubated in 20% acetic acid to destroy any endogenous 
alkaline phosphatase activity. Then they were rinsed in PBS pH 7.4, the 
excess buffer was wiped and 200 ul of PBS containing 0.1% normal 
serum was spread on the tissue to block the non specific binding of the 
antibody. The slides were incubated for 1 hour at room temperature 
in humidified box to reduce the evaporation.
The slides were washed with PBS, and 200 ul of the first antibody 
diluted in PBS-2% BSA were spread on the slides, and the slides were 
incubated at 4°C overnight in a humidified box.
The slides were then washed three times 10 minutes each with 
PBS- Tween, 200 ul of alkaline phosphatase labelled IgG diluted in 
PBS- 2% BSA was added to each slide and, incubated for 90 minutes 
at room temperature, they were washed again with PBS-Tween as 
before.
The substrate solution, 1 ml, was added to each slide, and the 
slides were incubated at room temperature for 45-60 minutes.The tis­
sues were washed with distilled water, tap water, then counter­
stained with Mayer’s haemalum for 4 minutes. The tissues were 
washed in running tap water until the colour was blue. Finally, the 
slides were mounted in glycerin jelly and left to dry. They were inves­
tigated using light microscope with 25 or 40 X lens.
5.2.5. Procedure for Horseradish peroxidase staining
The tissues were dewaxed as before, and the endogenous peroxidase 
was blocked by incubating the slides for 10 minutes in the blocking 
solution.
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After blocking the slides were soaked in running tap water for 
another 10 minutes, the excess water was removed, and the free sites 
were blocked with 1% normal serum in Tris-HCl pH 7.6 for 1 hour 
at room temperature.
The excess liquid was removed, 200 ul of the the first anti­
body (anti-hPTH(l-34) antibody) was added, and the slides 
incubated at 4°C overnight in a humidified box.
The slides were washed three times, 10 minutes each. Tris- HC1 
buffer containing 0.5% Tween 20, and 200 ul of the second antibody 
(HPROase labelled antibody) was added to each slide, and incubated for 
60 minutes at room temperature.
After washing three times with Tris-HCl-Tween as above, the 
slides were incubated with the substrate for 3-5 minutes depending 
upon the visual appearance of brown colour, the reaction stopped 
by immersing the slides in distilled water.
The tissue sections were placed in Elhrich’ acid heamatoxylin 
(supplied by R A Lamb Ltd) for 5 minutes. They were gently washed 
in running tap water for 5 minutes, followed by differentiation in acid 
alcohol (1% v /v  hydrochloric acid in 70% v /v  alcohol) with gentle 
agitation for approximately 5 seconds.
The sections were again rinsed in running tap water for 5 minutes 
and examined microscopically to ensure sufficient differentiation. 
They were rinsed in tap water for 10 minutes , and then progressively 
dehydrated by passing through 70% alcohol, 100% alcohol twice for 
30 seconds and finally cleared in xylene twice for 30 seconds and 5 
minutes respectively.
The sections were mounted using DPX (BDH chemicals Ltd) and 
a coverslip, taking them straight from xylene.
5.3. DOUBLE SANDWICH ELISA
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5.3.1. Materials
Polystyrene plates were supplied by Dynatech, Donkey ant- 
mouse and anti-goat HRPOase IgG labelled were obtained from Guil- 
dhay Antisera, Guildford Surrey.
5.3.2. Purification of goat anti-PTH antibody
5.3.2.1. Caprylic acid and ammonium sulphate precipitation 
method
The method was essentially that adapted by McKinney and Par­
kinson (McKinney and Parkinson 1987). The serum was diluted 
with acetate buffer 1:5 and the pH adjusted to 4.5. Caprylic acid was 
added slowly to the concentration of 25ul/ml of diluted sample while 
the solution was mixed. The solution was mixed for further 30 
minutes at room temperature, and the mixture centrifuged at 3000 
rpm in Beckman J6 refrigerated centrifuge for 15 minutes. The super­
natant was decanted, and cooled down by putting it on ice for 
10 minutes. The immunoglobulins were then precipitated using 
45% ammonium sulphate. Ammonium sulphate was added to the 
supernatant (277mg/ml); the solution was stirred for 30 minutes and 
centrifuged at 3000 rpm for 15 minutes in J6 Beckman refrigerated cen­
trifuge . The pellet was resuspended in PBS and dialysed overnight 
against 2 litres of PBS. The dialysate was kept at 4°C .
5.3.2«2. Anion exchange method
An DEAE anion exchange cartridge was made available by Guil- 
dhay Antisera Ltd. The column was equilibrated by running 50 ml of 
phosphate buffer pH 6.4. 1 ml of serum was added to 9 ml of phos­
phate buffer pH 6.4, and run through the column. The serum was 
washed down using the same buffer and, 5 ml fractions were collected. 
The column was washed with acetic acid, and regenerated again by 
washing it with phosphate buffer pH 8.8.
The protein content of the fractions was measured at 280 nm on 
Cecil spectrophotometer, and the protein concentration was calculated
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(Hudson and Hay 1980).
5.3.3. Purification of mouse monoclonal antibody
Mouse monoclonal antibodies were purified using Protein A as 
mentioned in chapter 3. The protein concentration was calculated as 
above.
5.3.4. Conjugation of monoclonal antibody w ith  HRPOase enzyme
The mouse monoclonal antibody was labelled with peroxidase 
according to Beyzavi et al ( 1987).
Buffers
Ethanolamine buffer pH 8.0: 5ml ethanolamine (BDH) was diluted 
to 50 ml with distilled water, 5ml glycine buffer (0.05M) was added 
and the pH was adjusted to 8.0 with 1M Hcl. The volume was made 
up to 100 ml with distilled water.
5.3.5. Method
HRPOase (10 mg) was dissolved in 2ml distilled water, and 0.4ml 
of 0.1M sodium periodate was added to the enzyme solution and 
mixed at room temperature for 30 minutes. The solution was then 
dialysed against ImM sodium acetate buffer pH 4.4 overnight at 4°C .
Affinity purified monoclonal antibody (5 mg) was dialysed 
against 0.1 M carbonate/bicarbonate buffer pH 9.5 overnight at 4°C .
The enzyme and antibody solutions were combined together 
and mixed for 2 hours at room temperature. Ethanolamine buffer pH 
8.0 (2 ml) was added and the solution was left standing for another 
hour before it was dialysed against two litres of PBS buffer pH 7.5. 
The labelled antibody was used without purification.
5.3.5.1. Double sandwich ELISA procedures
Titration of both monoclonal and polyclonal antibodies were car­
ried out, by coating the rows of ELISA plate with different concentra­
tions of one of them and, then incubating with hPTH. The second
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antibody was added at different concentrations in the columns of 
ELISA plate. The same procedure was used for both the antibodies. 
When the concentrations of the different antibodies were determined, 
the sensitivity was assessed using different concentrations of 
hPTH(l-34).
Both antibodies were tried as bottom layer and top layer in the 
assay. The general procedure is as follows:
The antibody was diluted in carbonate-bicarbonate buffer, pH 9.6, 
to concentrations of 20,10,5,2 and 1 ug/ml, 200 ul of solution was 
added to the appropriate wells and the plate incubated overnight at 
4°C . After washing the plates with PBS, the free sites were blocked by 
incubating 200 ul of PBS-BSA in each well for 1 hour at 37° C .
hPTH( 1-34),200 ul,2 ug/ml was added to all wells, and the incu­
bation continued for another 2 hours at 37°C . The plate was washed 
with PBS-Tween 20, anti-PTH antibody, diluted in PBS-BSA-Tween 
20 to 20,10,5,2 and 1 ug/ml, was added to the corresponding wells 
and the plate incubated overnight at 4°C .
The plate was washed with PBS-BSA-Tween 20, and 200 ul of 
second antibody HRPOase labelled was added to all wells and incu­
bated for 2 hours at 37° C . After washing, 150 ul of substrate was 
added to each well. After incubation for 30 minutes at 37° C . 50 ul of 
2M sulphuric acid was added to stop the reaction and the plate read at 
490 nm in automatic ELISA reader.
5.4. RESULTS
5.4.1. Immunocytochemistry
Monoclonal antibodies were titrated with HRPOase and ALP 
labelled anti-mouse IgG. The optimum dilution for each monoclonal 
antibody was established, as well as for the HRPOase and ALP anti­
mouse IgG. The optimum dilutions are described in table 5.2.
The antibody were screened first using HRPOase - labelled donkey 
anti-mouse IgG. The tissue sections were blocked and the antibody was
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allowed to react to the tissue, the bound antibody then revealed using 
HRPOase -labelled antibody and DAB. The positive was dark brown 
colour, while the negative shows no brown colour in the tissue. The 
results of HRPOase system are shown in plates 5.1 - 5.8.
The results obtained using HRPOase system consistently gave high 
background staining. This made the distinction between the positive 
and negatie staining very difficult. The chromogen used (DAB) occa­
sionally was found to give inconsistant results. The staining was light 
in all of the antibodies tested, and changing the HRPOase dilution 
always led to increased background staining. However, with careful 
microscopical examination positive signs could be seen.
The same tissue sections were used with ALP labelled anti-mouse 
antibody. The titres were determined as previously described with 
HRPOase and they are given in table 5.2.
The use of ALP labelled anti-mouse was found to give better 
results than HRPOase labelled antknouse antibody, the background 
was low and the positive was clearly visible as the red colour is very 
much recognizable. All the antibodies tested were found to be positive; 
some were weak and the colour was not very strong. The results 
were consistent unlike the experience with HRPOase where a great deal 
of variation was seen between different batchs of DAB (chromogen). 
The outcome of the experiments with ALP-labelled anti-mouse anti­
body are shown in plates 5.9 - 5.14.
5.4.2. Double sandwich ELISA
The goat anti-hPTH(l-34) antiserum was purified using precipi­
tation and anion exchange resin. The precipitation method yielded a 
relatively pure material as judged by SDS-PAGE analysis shown in 
plate 5.15. However, the antibody comprised only 10% of the total
APPLICATION OF MONOCLONAL ANTIBODIES
- 163 - CHAPTER 5
Plate 5.1: The binding of monoclonal antibody 4/PTH/NS1 
to chief cell carcinoma tissue . Using HRPOase labelled an ti­
body.
* %
Plate 5.2: The binding of monoclonal antibody 4/PTH/NS2 to 
chief cell carcinoma tissue . Using HRPOase labelled antibody.
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Plate 5.3: The binding of monoclonal antibody 4/PTH/NS3 
to chief cell carcinoma tissue . Using HRPOase labelled an ti­
body.
, v  •  A *
m m m
i  *
K   m F n
Plate 5.4: The binding of monoclonal antibody 5/PTH/SP1 
to chief cell carcinoma tissue . Using HRPOase labelled an ti­
body.
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Plate 5.5: The binding of monoclonal antibody 5/PTH/SP2 
to chief cell carcinoma tissue . Using HRPOase labelled an ti­
body.
Plate 5.6: The binding of monoclonal antibody 5/PTH/SP3 
to chief cell carcinoma tissue . Using HRPOase labelled an ti­
body.
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Plate 5.7: The binding of monoclonal antibody 5/PTH/SP7 
to chief cell carcinoma tissue.Using HRPOase labelled an ti­
body.
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Plate 5.8: Negative control. Monoclonal antibody omitted, 
a ll other steps are the same. Using HRPOase labelled an ti­
body.
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Plate 5.9: The binding of monoclonal antibody5/PTH /SP4 
to chief cell carcinoma tissue.Using ALP labelled antibody.
Plate 5.10: The binding of monoclonal antibody
5/PTH/SP2 to chief cell carcinoma tissue.Using ALP 
labelled antibody.
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Plate 5.11: The binding of monoclonal antibody
5/PTH/SP4 to chief cell carcinoma tissue.Using ALP 
labelled antibody.
Plate 5.12: The binding of monoclonal antibody
4/PTH/NS6 to chief cell carcinoma tissue.Using ALP 
labelled antibody.
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Plate 5.13: The binding of monoclonal antibody
5/PTH/SP4 to chief cell carcinoma tissue.Using ALP 
labelled antibody.
m
Plate 5.14: The binding of anti-insulin  monoclonal an ti­
body to chief cell carcinoma tissue(used as a negative con­
trol). Using ALP labelled antibody.
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Plate 5.15: SDS-PAGE analysis of caprylic acid and 
ammonium sulphate precipitated goat antibody. Ca) 
Goat serum before purification (b) Goat IgG (c) 
Caprylic acid/ammonium sulphate purified goat an ti­
body (d) Molecular weight m arker. 7.5% acrylamide 
under reducing conditions was used according to the 
method of Campbell 1984.
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immunoglobulins precipitated and the use of acid and ammonium sul­
phate caused some destruction of antibody.
In anion exchange chromatographis purification, the antibody 
eluted in one peak collected in three tubes, and the tubes were kept 
separate. The protein was monitored at 280 nm and the concentration 
was calculated accordingly. The elution of the antibody from the 
anion exchange column is shown in figure 5.1. Fraction number 3 was 
found to contain more protein and gave a higher binding to hPTH(l- 
34). In indirect ELISA, therefore, it was used in all studies.
5.4.3. Assay
Chequerboard ELISA of both goat anti-hPTH(l-34) polyclonal 
and mouse monoclonal antibodies were carried out using hPTH(l-34) 
only. Different concentrations were used to assess the sensitivity of 
the assay.
The monoclonal antibodies were tested as a solid phase first to 
assess their capability to bind to hPTH(l-34). This was considered 
to be the appropriate use of these low affinity antibodies, especially 
when the material is available in large amount and also can be produced 
relatively easily. The results from three different monoclonals are 
shown in figures 5.2 - 5.4. The binding of hPTH(l-34) was time 
dependent ,as an increase in the binding was observed when the anti­
body was incubated with hPTH(l-34) for up to 48 hours as shown in 
figure 5.5. There were also no difference in the binding value between 
the antibodies when tested in a standard curve (figure 5.6).
The response using monoclonal antibodies as solid phase was not 
sufficiently high, even when concentration of hPTH(l-34) far higher 
than normal blood levels, was used. Then goat polyclonal antibodies 
were used as solid phase. Again different concentrations were tested 
against different concentrations of mouse monoclonal antibodies, and 
different concentration of hPTH(l-34). The
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Figure 5.1: The elution profile of goat serum from anion 
exchange disc.
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results are shown in figures 5.7 - 5.9.
Mouse monoclonal was labelled using the periodate method, and 
used in the assay instead of anti-mouse labelled antibody. The titration 
of the labelled monoclonal was shown in figure 5.10. The use of 
HRPOase labelled monoclonal antibody in hPTH(l-34) ELISA standard 
curve was shown in figure 5.11. It is clear that the sensitivity of the 
assay using the enzyme labelled monoclonal antibody is low. The addi­
tion of more concentrated labelled monoclonal antibody only increases 
the NSB rather than increasing the sensitivity. There seems to be a 
cross-rectivity between the goat and mouse antibodies. This can be seen 
in the difference between the blank and the negative controls used. 
When the wellswere not coated with the antibody the reading was low, 
whereas with antibody coating in the absence of antigen the reading 
was high. It is also confirmed when simply goat and mouse antibodies 
were mixed and incubated in plastic tube before the addition to an 
antigen coated plate, no binding was observed i.e no effective mono­
clonal antibody left to bind the hPTH(l-34) on the plate.
It is apparent from the above studies that monoclonal antibodies 
are only effective when used as top layer. However, eventhough the 
combination of polyclonal and monoclonal antibody was shown to 
work in sandwich ELISA for hPTH(l-34), the sensitivity of the assay 
was not sufficient for it to be used in the detection of hPTH(l-34) in 
body fluids.
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Figure 5.10: Titration of enzyme labelled monoclonal anti­
body 5/PTH/SP2 in sandwich ELISA for hPTH(l-34). 20 
ug/ml goat antibody was used as bottom layer and 2 ug/ml 
hPTH(l~34) added and incubated overnight at 4°C .
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5.5. DISCUSSION AND CONCLUSION
The immunocytochemical studies demonstrate the binding of 
antibody to the native hormone(s). It is important that they recog­
nize the native hormone in the tissue or serum if they are to be 
used in clinical studies. It is the first study to demonstrate the binding 
of monoclonal antibodies raised against synthetic hPTH to parathy­
roid tissue. The binding of these monoclonal antibodies to parathyroid 
tissue containing hPTH, might be useful in localizing tumors secreting 
hPTH in tissues other than the parathyroid gland, or in localizing and 
possibly estimating the size of adenomas in parathyroid glands.
The double sandwich ELISA developed for the measurement 
of hPTH(l-34) demonstrates the analytical potential of the mono­
clonal and polyclonal antibody produced. From the studies carried out 
using both the monoclonal and polyclonal antibodies,it is apparent 
that the affinity of the monoclonal antibodies is not suitable for 
detecting very low concentration of hPTH(l-34). Therefore, this assay 
cannot be used in clinical assessment of patient samples since the nor­
mal range is far lower than that possible with this assay. The use of 
high non- isotopic label may improve the sensitivity.
The use of monoclonal antibody as a solid phase (capture 
antibody) was found to be inferior to that of polyclonal antibody. 
This could be related to the specificity and the possible alteration of 
binding site of the monoclonal antibodies. Other explanation might be 
the singular specificity of monoclonal antibody with probably one or 
near that number of antigenic determinant units per antigen molecule. 
Hence the limited signal intensity observed. Indeed the sensi­
tivity of immunoassays and the affinity of antibodies was shown to be 
enhanced by the mixing of monoclonal antibodies (Elhrich and Moyle 
1983, Elhrich et al., 1982, Moyle et al., 1983).
The labelling of the monoclonal antibody did not increase the 
sensitivity of the assay. Also the increase in concentration of the 
labelled monoclonal antibody did not improve the assay in this
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respect contrary to the: report of Wada (Wada et al., 1982). The use of 
low concentration of labelled antibodies, on the other hand was sug­
gested to be better in constructing a calibration curve (Tshikawa et 
al., 1982). In the former study, the dilution of labelled monoclonal 
antibody showed very little difference to the sensitivity, ivity.
In double site ELISA, the use of monoclonal antibody as a top 
layer proved to be superior to their use as solid phase (capture anti­
body). This could be related to the fine specificity of monoclonal anti­
body, and the possible alteration of the binding site of monoclonal 
antibody upon adsorption can not be precluded.
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Both radioimmunoassay (RIA) and enzyme linked immunosorbent 
assay (ELISA) were chosen for screening for monoclonal antibodies to 
hPTH(l-34) , because they comply with the essential features of the 
screening assays mentioned in chapter 2 i.e fast, reliable and can handle 
large numbers of samples. It was expected that the combined use of 
these two fundamentally different techniques (Ekins 1981) would 
allow the selection of antibodies with different characteristics (Miller 
et al., 1986). Both assays were found to be very suitable for evaluating 
the polyclonal antisera as well as for screening the monoclonal antibo­
dies in tissue culture supernatants. The liquid phase RIA was used for 
the screening of monoclonal antibodies in all fusions. However, in prac­
tice the liquid phase assay was not the most valuable in detecting 
monoclonal antibodies. Different methods were used to enhance the pre­
cipitation of antigen-antibody complexes. The second antibody and PEG 
method was found to be the best, because it gave the lowest non­
specific binding in comparison with the dextran coated charcoal (Zanelli 
et al., 1983 ). The liquid phase RIA was found to be particularly useful 
in screening for goat monoclonal antibodies specific to hPTH(l-34). 
This is the first occasion in which goat monoclonal antibodies have been 
produced and detected.
The iodination of hPTH(l-34) is difficult and the most commonly 
used methods often result in substantial damage to the hormone 
(Teitelbaum 1983) and yield a less immuno-active peptide. In this 
study a method using iodogen (1,3,4,6-tetrachloro-3a,6a- 
diphenylglycoluil) was developed. Although iodogen method has been 
used for the iodination of other peptides (Schrader and O’Malley 1981), 
this is the first report of it being used for hPTH. This iodogen method 
was found to be superior to the chloramine T method in iodinating 
hPTH(l-34). The incorpoation of iodine into hPTH(l-34) was higher as 
indicated by the elution profile of the labelled hormone from sephadex 
G15 column. The labelled hormone from the iodogen method resulted 
in higher binding than that obtained from the chloramine T method as 
indicated by the antiserum dilution curve. Results from this study also
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show that 1.5 mCi sodium iodide used in many published protocols is 
unnecessary (Zanelli et al., 1980), and that only one third is required 
for iodination. This can be seen from the elution profile of the .125I  
-hPTH( 1-34) from the G15 column, where the labelled peak using 
iodogen gave twice the number of counts per second than that of 
chloramine T. Moreover, less damage to the peptide occured in the 
iodogen method; this was evident since all iodinated fractions from the 
iodogen method were useable in the assay, whilst only one fraction 
with high binding was seen after chloramine T iodination.
ELISA provided an effective, fast, reliable method which could 
handle a large number of samples with ease. The application of ELISA 
procedure B (using antigen non-coated wells as blanks) was successful 
in avoiding the detection of false positives. This criteria has been 
adapted by many workers for the same reason (Cheng 1988, Kenna et 
al., 1985). Blocking agents are not all effective in preventing non­
specific binding to the wells of ELISA plates (Kenna et al., 1985). 
While gelatin and bovine serum albumin were found to have the same 
effect in blocking the free sites of the wells of ELISA plates, the use of 
casein in our hands blocked even the binding of the antibody. The 
detergent Tween 20 was found to prevent the binding of rat antibody 
to solid phase antigen. Interestingly, this is a widely used detergent in 
ELISA. It is normally used for washing and in antibody dilution 
buffers. However, recently it has been shown both to enhance (Cheng 
and Yap 1988, cheng 1988) and decrease (Gharavi and Lockshin 1988) 
the binding of human anticardiolipin antibodies. It seems from our 
results that this effect may depend on the antibody characteristics. It is 
noteworthy that the binding of mouse and goat antibodies is not 
affected.
Only four published papers describe attempts to produce mono­
clonal antibodies to hPTH (Nussbaum et al., 1981, Van De Walle et al., 
1983, Nussbaum et al., 1985, Vieira and Neer 1987). In most studies 
bovine parathyroid hormone (bPTH) was used as immunogen and 
screening is for antibodies that cross-react with hPTH. There are
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significant differences in amino-acid sequence between hPTH and bPTH 
(Arnaud 1983), and these have been shown to affect the antibody 
characteristics (Mallete 1983, Zanelli et al., 1983a). It has been shown 
that the use of hPTH in the production of polyclonal antibody resulted 
in more specific antibodies to hPTH (Mallette 1983, Vieira et al., 1987). 
Furthermore, with the availability of synthetic hPTH and fragments, 
although expensive, their use as immunogens may lead to a more 
specific antibody.
We report the successful production of monoclonal antibody to 
hPTH(l-34) using the synthetic N-terminal hPTH(l-34) sequence as 
immunogen. The results of this study represent a good basis for the 
immunization and production of rodent monoclonal antibodies to 
hPTH(l-34). The mouse system has many advantages and is generally 
preferred for the production of monoclonal antibodies (Goding 1986, 
Campbell 1984). With the exception of our research work, all mono­
clonal antibodies produced against PTH so far are of mouse origin. 
However, Balb/c mice were found to be good responders when immun­
ized with bPTH, and have been used successfully in the production of 
monoclonal antibodies (Van De Walle et al., 1983). In our hands Balb/c 
mice were found to respond when immunized with hPTH(l-34) conju­
gated to a carrier protein, contrary to previous reports that Balb/c mice 
are poor responders to hPTH(l-34) (Nussbaum et al., 1985), in which 
the authors attributed the poor response to genetic control. Results 
from our study, of the route of immunization and the form of antigen 
illustrate that Balb/c mice do respond to hPTH(l-34) and their 
response depends on the form of antigen. The free peptide was found to 
be non-immunogenic but produced a response when conjugated to a car­
rier protein. The route of immunization in the mouse has not been 
investigated thoroughly using the conjugated hPTH(l-34). The intra- 
peritoneal route of immunization was used in the mouse and proved 
successful for the conjugate, but not the free hPTH(l-34). The 
intramuscular and intradermal routes of immunization produced no 
response when the free peptide was used as immunogen. The high cost
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of the antigen prevented a full investigation of immunogenicity and the 
response.
A novel in vitro immunization was used in the production of 
monoclonal antibodies to hPTH(l-34). This method has proved success­
ful in producing monoclonal antibodies against calmodulin when the in 
vivo immunization had failed (Pardue et al., 1983) and has been used 
to increase the number of positive clones in fusion (Siraganinan et al., 
1983). In this study, the method has resulted in the successful produc­
tion of monoclonal antibodies to hPTH(l-34), when the use of the in 
vivo immunized spleen cells has failed. Moreover, all the antibodies 
produced were of IgG class which probably indicates a secondary 
response. Eleven cell lines were established as positive to hPTH(l-34) 
using ELISA. However, none showed any binding to radio-labelled 
hPTH(l-34) in liquid phase RIA. This was probably because of the 
specificity of the antibodies and/or the possible structural alteration in 
the antigen during iodination. Indeed, Nussbaum investigated several 
other molecules in which amino acid substitution was made specially to 
aid the iodination of hPTH(l-34), but despite such manipulation good 
antigen-antibody binding was not achieved (Nussbaum et al., 1981).
In immunocytochemical studies using the mouse monoclonal anti­
bodies to hPTH(l-34), one antibody gave very strong positive binding 
to chief cells. All hybridoma lines tested were found to bind with the 
tissue antigen(s), though some rather weakly. Thus their binding to the 
natural hormone was demonstrated. It is expected that these cell lines 
will be of significant value in such studies, and they could used in the 
clinical detection and/or localization of PTH tumors. The mouse antibo­
dies were unfortunately found to be of low affinity which makes them 
unsuitable for hPTH(l-34) immunoassay purposes. This is because the 
assay is very demanding in terms of antibody affinity, especially when 
the level of circulating hPTH(l-34) is markedly low in comparison 
with other forms of the hormone which circulate in 10-15 fold higher 
concentration.
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Rats are not often used for the production of monoclonal antibo­
dies. In most publications the use of rats was reserved for the produc­
tion of monoclonal antibodies to mouse antigens. The rat spleen cells 
are usually fused with mouse myeloma cell lines, but very rarely with 
rat myeloma cell lines. This could be as a result of the difficulties 
encountered in growing the parent myeloma line or equally the result­
ing hybrids. Here we report our experience with the rat Y3 myeloma 
cell line, and the first successful cross-species rat monoclonal antibodies 
to hPTH(l-34). Investigation of the immunogenicity was carried out in 
a similar way to that for mice. The route of immunization was investi­
gated first using the free hPTH(l-34). Surprisingly, the results show 
substantial differences between mice and rats. Rats responded to 
immunization with the free fragment (1-34), but only when immun­
ized intramuscularly. Intraperitoneal and intradermal immunization 
routes proved completely unsuccessful. The use of the free synthetic 
fragment was preferred, because it has a unique tertiary structure in 
solution quite distinct from the whole molecule, while conjugation to a 
carrier protein carries the risk of changing this conformation (Atassi 
1986). In contrast to mice in which conjugation was necessary, rats 
responded very well to the free peptide.
Rat-rat fusion has certain advantages. It is probably that the 
difficulties of maintaining the rat myeloma cells have been the major 
reason underlying the poor use of rat-rat fusions in monoclonal anti­
body technology. In this study Y3 rat myeloma cell line was used as 
fusion partner. Even though different conditions were used for cell 
maintenance, fusion experiments conducted with this cell line were not 
successful. Rat-mouse cross-species fusion, on the other hand, looked 
very promising. These fusions resulted in six positive cell lines, all of 
which produced IgM class antibodies. The production of IgM in such a 
situation was somewhat surprising. It is possible that only a primary 
immune response was generated in the responding rats.
The goat polyclonal antibody binds both the whole molecule 
hPTH(l-84) and hPTH(l-34). The cross-reactivity study with PTH
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peptides suggests that the antibody binds to the C-terminal end of the 
hPTH(l-34), the same region recently identified as antigenic region in 
the hPTH(l-34) (Vieira and Neer 1987). This antibody might be useful 
in setting up immunoradiometric or immunochemiluminometric assays 
similar to those described before (Brown et al., 1987, Nussbaum et al., 
1987, Brown et al., 1988). The goat responded well to hPTH(l-34) and 
allowed the production of a novel heteromyeloma by cross- species 
fusion. This differs from the normal heteromyeloma fusion in the sense 
that genetic contribution from three different species is involved; a 
mouse- sheep heteromyeloma was fused with goat peripheral blood 
lymphocytes. The outcome of this was a hetero-hybridoma, generated 
for the first time, which produce goat monoclonal antibodies with good 
specificity to hPTH(l-34). The fusion efficiency was found to be very 
high (100%). Unfortunately these hetero-hybridomas lost their ability 
to secrete antibody 10 days after the screening assays gave positive 
results.
FUTURE WORK
This study provides a substantial amount of valuable background 
material for the raising of monoclonal antibodies to hPTH-related pep­
tides. On the basis of the findings presented here, the following research 
work would be extremely valuable: (a) Affinity purification of the 
monoclonal antibodies described above and labelling, for example, with 
radio-label, for use in immunoassay, (b) Examination of the fusion 
efficiency of Y3 rat myeloma cell line and optimization of rat-rat 
fusions; continuation of rat-mouse work particulary in the light of the 
good primary response of the rat; testing of primary in vitro immuniza­
tion with a view to incorporating it into the routine immunization pro­
tocol, (c) Development of goat-mouse non-secretor hybridomas for the 
use as fusion partners; the use of second and third generation hybrido­
mas in particular as fusion partners is required for the production of 
stable and continuously-secreting hetero-hybridomas, (d) Further stu­
dies of the use of fragments of hPTH for raising monoclonal antibodies
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to hPTH, thereby opening up new areas of research on the structure and 
functions of parathyroid hormone.
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A B ST R A C T
Monoclonal antibodies against the b iologically  a ctiv e  N -term inal 
fragm ent of human parathyroid hormone, hPTH (1-34), w ere produced. The 
procedure included the use of novel secondary im m unization in vitro of mouse 
spleen ce ll cu ltures. D issociated  spleen ce lls  from primary im m unized B alb /c  
m ice, w ere cultured for five days in the presence of thym ocyte conditioned  
media (TCM) and synthetic  hPTH (1-34). Contrary to previous findings by 
other workers, in our hands B alb /c m ice responded w ell. Follow ing  
im m unization the spleen ce lls  w ere fused with NS1 m yelom a ce lls  and 
cultured for eleven  days before screening for antibody. Using an enzym e  
linked im munosorbent assay (ELISA) a number of positive clon es w ere  
d etected .
P ositive  c e lls -w e r e  cloned by lim iting dilution and fifte e n  sp ec ific  
m onoclonal hybridomas w ere produced. The immunoglobulin c lass of the 
d ifferen t m onoclonal antibodies was found to be IgG l. The 
im m unocytochem ical reaction  was tested  with ch ie f ce ll carcinom a tissue  
and found to be clearly  positive.
IN TRO DUC TIO N
Parathyroid hormone (PTH) is an 84 am ino-acid single polypeptide  
chain, with a m olecular w eight of 9300 D altons. PTH serves an im portant role 
in the regulation o f extracellu lar calcium  lev e l, which is m ediated by its  
e f fe c ts  on kidney, bone and gut. Plasm a contains a heterogeneous m ixture of 
PTH fragm ents (1,2) largely o f carboxy-term inal fragm ents o f PTH, and only 
2-25% in tact PTH (3). While the main form of the hormone secreted  by the  
parathyroid glands is the in tact PTH (4), m etabolism  by the liver and perhaps 
the kidneys, represents the final activation  of this hormone thus contributing  
to the presence of these PTH -related peptides in circulation .
It is generally accep ted  that the N -term inal fragm ent of PTH contains 
the structural requirem ents for the physiological a c tiv ity  (5), and to date the 
C -term inal fragm ent has not been assigned any hormonal function.
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It appears from published reports that serum N -term inal PTH leve ls  are 
useful in discrim inating betw een  healthy subjects and hyperparathyroid  
p atients (6 ,7 ,8 ,3 ,9 ,10) in venous ca th eteriza tion  studies for loca liza tion  of 
parathyroid tissue (11), ' hypercalcaem ic secondary hyperparathyroidism , 
chronic renal failure, and in the investigation  of the pharm acokinetics of 
exogenously adm inistered hPTH (1-34) (12,13). H ow ever, from  the view  point 
of reliab ility  and sen sitiv ity  the current N -term inal PTH im m unoassays based 
on polyclonal antibodies are far from adequate for this purpose (14). We, 
therefore, undertook in the present study, the developm ent of m onoclonal 
antibodies to h-PTH (1-34) which m ight offer an im provem ent in som e of the 
laboratory investigations o f calcium -related  disorders.
M ATERIALS A N D  M ETHODS
Im m unization and C ell Fusion:
B alb /c m ice were im m unized with hPTH (1-34) conjugated with bovine 
serum albumin, and then im m unized with unconjugated hPTH (1-34) for two 
more doses within four w eeks. N ovel secondary in vitro im m unization of 
spleen ce lls  was carried out by a m ethod sim ilar to that reported previously 
(15). A fter  five days of in vitro im m unization, the spleen ce lls  w ere fused  
with NS1 m yelom a ce lls  in the ratio of 5:1 using polyethylene g lycol, M.W. 
1500, (16). The ce lls  w ere plated out in four 24 w ell tissue culture p lates, 
containing feeder layer ce lls  in two tim es the normal concentration  of 
hypoxanthine, aminopterin. and thym idine (HAT). The p lates were incubated  
at 37 C in a hum idified atm osphere of 5% CCL for eleven  days. Those w ells 
which showed positive growth when exam ined under the m icroscope w ere 
screened using indirect ELISA.
ELISA:
Figure 1 shows the indirect ELISA assay which has been adapted for 
screening the culture supernatants for the presence of the desired antibodies. 
A 200 yl aliquot of hPTH (1-34) solution, at a concentration  of 1 yg /m l in 
phosphate buffer saline (PBS), pH 7.4 was added to each w ell of a 96-w ell 
polyvinylchloride p late. A fter  incubation overnight the p late was washed 
three tim es w ith PBS pH 7.4 containing 0.1% gelatin  and 0.05% tw een 20. The 
sam ple or standard was added to the p late, incubated at 37°C  for two hours 
and washed as before. The next step  was the addition of peroxidase-labelled  
donkey anti-m ouse second antibody to each w ell, incubation at 37°C  for 
another tw o hours, follow ed by m easurem ent o f the colour developed at 
490 nm thirty m inutes after the addition of orthophenylene diam ine (OPD) as 
substrate for peroxidase.
D eterm ination  of Immunoglobulin C lasses and Subclasses:
The m onoclonal antibodies w ere allowed to react with immunoglobulin  
class sp ec ific  anti-sera (Serotec) in im m unodiffusion tes ts .
These antibody characterisations w ere further confirm ed using double 
antibody sandwich ELISA. P olystyrene m icrotitre p lates w ere coated  with 
donkey anti-m ouse im munoglobulins (Guildhay, Guildford, U.K.) and the 
supernatants allowed to bind to it. The sheep c la ss-sp ec ific  an ti-sera were 
then diluted 1:1000 and applied to the p late.
Donkey anti-sheep  antibody labelled  w ith horseradish peroxidase 
(Guildhay) was added and allowed to react for one hour at 37°C . The p late  
was washed and the enzym e visualised using an orthophenylene diamine (OPD) 
reaction .
Im m unocytochem istry:
P araffin  waxed ch ie f ce ll carcinom a tissue s lices  6-8 ym w ere dewaxed  
and the endogenous alkaline phosphatase blocked, the free s ite s  w ere also
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Step  1
S t e p  2 PTH
1 - 3 4
PT H
1 - 3 4
S t e p  4
PTH
1-34
FIGURE 1 ., Indirect ELISA o f Human Parathyroid Hormone (1-34) S p ec ific
M onoclonal A ntibodies.
Step‘1 - A dsorbtion of ly g /m l antigen to polyvinylchloride
p late overnight at 4 C.
Step 2 - Addition of cu ltu re supernatant antibody and
incubation for 2 hours at 37 C.
Step 3 - The addition of enzym e labelled donkey an ti-m ouse
antibody and incubation for 2 hours at 37 C.
Step 4 - The addition o f en zym e substrate, orthophenylene
diam ine (OPD) and incubation for 30 m inutes at 
37 C. Sulphuric acid  addition to stop the reaction .
blocked using 1% non-immune sera. Supernatant (200 yl) from  growing ce lls  
was spread over the tissue and incubated at 4°C  overnight. The tissues w ere  
washed using phosphate buffered saline and 200 yl of alkaline phosphatase 
conjugated antibody was added. Incubation was continued for a further one 
hour at room tem perature. A fter  washing, the colour was visualised using 
naphthol AS:BI and fast red.
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RESULTS
Sera from m ice im m unized with hPTH (1-34), w ere used to se le c t  the 
conditions for the ELISA system . A chequerboard ELISA for positive mouse 
serum is shown in Figure 2. From the screening te s ts  for m onoclonal antibody 
against hPTH (1-34), a number of positive w ells w ere d etected . The ce lls  
w ere cloned tw ice  using a lim iting dilution m ethod. A to ta l of f ifteen  ce ll 
lines w ere identified  as positive and the corresponding hydridomas stored in 
liquid nitrogen.
The im munoglobulin class and subclass w ere found to be IgGl by 
im m unodiffusion and confirm ed using ELISA. The resu lts are given in Figure
3.
In im m unocytochem istry, one clone was tested  and found to give a 
positive result with tissue s lices  from a ch ie f c e ll carcinom a as shown in 
Figure 4.
2 -.00
1 .8o
1 . 4 0
1 . 2 0
l.oo
.80
. 6 0  J
. 4 0 -B -
. 2 0
.00
. 5 0 1 . 5 0 2 . 5 01.00 2 .00.00
Antigen coating concentration pg/ml
FIGURE 2., T itration o f B alb/c m ice antiserum  to human parathyroid  
:hormone (1-34) using d ifferen t antigen concentrations for 
coating of the plate.
A ntiserum  dilution - 1:1,000 ( • ----- • ) ,  1:2,000 (■ ■ ),
1:4,000 (▼-----▼ ), 1:8,000 (♦ -----*  ), 1:16,000 (□------□ ),
1:32,000 (A.------ A ) , 1:64,000 (O------O)
IgGl IgG2a IgG3 Igfl
I qo C l a s s  & S u b c l a s s
FIG U R E  3., Typing  o f  fo u r  M o n o c lo n a l  a n t ib o d ie s  using  doub le  a n t ib o d y  
sa n d w ic h  ELISA.
1 /3 /6  ( m ) ,  1 /2 /6  ( @ ) ,  2 /2 /6  ( « ) ,  C 8  ( * ) .
f
:J L
' Jk V
**- * «# • v ' 4- 
U AUiir * -
. -  ; ..
4:
#
I
vy  '^ C > ;■ ^  »**<
•ttt T
#*1 4#'
FIG U R E  4.,  (a) T h e  b ind ing  o f  M o n o c lo n a l  a n t ib o d y  to  hP T H  in s e c t i o n s
f ro m  p a r a t h y r o id  c h ie f  c e l l  c a r c in o m a  t i s su e ,  
c o u n te r s t a i n e d  w i th  h a e m a l u m  (x 400).
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F IG U R E  4.,  (b) T h e  s a m e  c o n d i t i o n s  as  in (a) e x c e p t  t h a t  insulin
M o n o c lo n a l  a n t ib o d ie s  w e r e  used  as  a n e g a t iv e  c o n t r o l  
(x 400).
DISCUSSION
S p e c i f i c  a n t ib o d y  to  hP T H  (1-34)  is n e e d e d  b e c a u s e  th is  f r a g m e n t  is 
b io lo g ic a l ly  a c t i v e ,  an d  i t s  m e a s u r e m e n t  is o f  g r e a t  i m p o r t a n c e .  T he  
a v a i l a b i l i t y  o f  m o n o c lo n a l  a n t ib o d y  to  th is  f r a g m e n t  should  o v e r c o m e  so m e  of 
t h e  i n h e r e n t  p r o b l e m s  o f  th e  a s sa y ,  a n d  m a y  a l low  th e  m e a s u r e m e n t  of  th is  
f r a g m e n t  in n o r m a l  in d iv id u a ls  w h ic h  is n o t  p o ss ib le  w i th  th e  e x is t in g  
p o ly c lo n a l  a n t ib o d y .  T h e  a n t ib o d ie s  r e p o r t e d  h e r e  p r o d u c e d  by i m m u n iz a t io n  
m v i t r o  m a y ,  t h e r e f o r e ,  h a v e  an  i m p a c t  on th e  in v e s t ig a t io n  o f  p a r a t h y r o id  
d i s o r d e r s  by im p ro v in g  th e  hP T H  (1-34)  a s sa y .
B a lb / c  m ic e  h a v e  b e e n  r e p o r t e d  to  be  ve ry  p oor  r e s p o n d e r s  to  hP T H  (1- 
34) (17). In c o n t r a s t ,  w e  fo u n d  t h a t  th is  s t r a in  o f  m ic e  r e s p o n d e d  w ell  to  
h - P T H  (1-34).  F u r t h e r m o r e ,  t h e  im m u n o g lo b u l in  c la s s  in ou r  p r e p a r a t i o n s  
w e r e  o f  t h e  IgGl t y p e ,  w h e r e a s  N u s sb a u m  (17) fo u n d  th e m  all  to  be  IgM. In 
t h e  c a s e  o f  b ov ine  P T H  im m u n o g e n ,  B a lb / c  m ic e  w e r e  r e sp o n s iv e  w hen  used  
f o r  th e  p r o d u c t io n  o f  m o n o c lo n a l  a n t ib o d ie s  (18). M o s t  of  t h e s e  a n t ib o d ie s  
w e r e  r e p o r t e d  to  be  IgG c la s s  w i th  only one  b e in g  IgM.
In c o n c lu s io n ,  w e  h a v e  show n  t h a t  B a lb / c  m o u se  sp le e n  c e l l s  re sp o n d  
w el l  to  h u m a n  P T H  (1-34) and  c a n  be used  fo r  m o n o c lo n a l  a n t ib o d y  
p r o d u c t io n .  T h e  ro le  o f  jn  v i t r o  im m u n i z a t io n  in thrs  r e s p e c t  c a n n o t  be  
d i s c e r n e d  a t  th is  s t a g e  o f  our  s tu d y .  F u r t h e r  w o rk  on th e  c h a r a c t e r i s a t i o n  of 
t h e s e  a n t ib o d ie s  and  t h e i r  a p p l i c a t io n s  is in p ro g re s s .
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